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Abstract
The technology of interfacing neurons with machines through implantable neural
electrodes has significant implications. Although there have been studies implanting such
electrodes in human to help patients with motor disorders, longevity of these implants
remains an unresolved issue. One of the key factors influencing longevity has been
adverse tissue response toward the implanted electrodes
The objective of this research is to engineer a comprehensive solution that can
manage the response at the cellular level while preserving the electrode functions. Given
the complexity of the host response, we hypothesize that a multi-pronged approach would
better improve the longevity of the electrodes. Specifically, we emphasize the importance
of modulating the inflammatory response from glial cells and directly protecting neurons
from oxidative stress induced death. To achieve this goal, a range of polymeric
therapeutics (i.e., prodrugs) capable of anti-inflammation and anti-oxidation were
designed and synthesized. These polymers were fully characterized for their structural
properties and therapeutic effects. Applications of these prodrugs onto the electrodes
were achieved using the versatile layer-by-layer (LBL) technique, which enabled the
preservation of electrical properties of the electrodes. These in vitro studies laid down the
foundations for future in vivo investigations of the efficacy of such a multi-pronged,
integrated therapeutic approach for modulating host tissue response. Furthermore, the
synthesized prodrugs can be applied for other types of medical implants, where
inflammation and oxidative stress are common characteristics of the host response to
those implants.
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The other approach to achieve therapeutic delivery is the use of stimuliresponsive polymers. Based on the lower critical solution temperature (LCST) behaviors
of poly(N-vinyl-2-caprolactam) (PVCL) polymers, its functional derivatives with pHdependent LCST behaviors were designed via copolymerization with a functional
derivative of VCL for smart drug delivery. Sharp and reversible response was observed
across a broad range of pH values. PVCL copolymer was demonstrated to be noncytotoxic at low concentrations. LBL compatibility of the copolymer was also explored.
The ultimate goal is to correlate the pH-sensitivity of the PVCL copolymers with the
tissue acidosis phenomenon to regulate therapeutic release.
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Chapter 1
Introduction

1

1.1 Neural Interface
Chronically implanted recording electrode arrays have the potential to improve
the quality of life of patients suffering from partial or full paralysis.[1-3] Such arrays can
be implanted into the cortex of a patient’s brain and the extracellular potentials from
nearby neurons are recorded, allowing the information encoded to control external
devices.
1.1.1 Physical design of neural electrodes
Neural electrodes have evolved from glass to metallic materials over the years.
The dimension of neural electrodes has also been decreasing constantly for the ease of
handling and minimizing damage to brain tissue, with the help of technology
advancement, especially the silicon micromachining development. The most common
modern models include Utah and Michigan type electrodes (Figure 1). The Michigan
type electrode has been widely used for many years because of its diversity. Hundreds of
designs and configurations have been developed and these electrodes could be connected
with the Integrated Circuit (IC) technology, realizing large amount of data collection and
analysis. The structure of such a micromachined electrode is shown schematically in
Figure 2. The bulk of the electrode is based on a silicon substrate. The recording sites are
made from conductive metals such as gold. There is one company focusing on
developing and manufacturing various types of electrodes for research and clinical
applications. The size of the recording sites of the Michigan electrode used in our study is
on the order of micrometer (Figure 3).
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Figure 1.. Examples of Utah and Michigan type neural electrodes. (a) Scanning electron
micrograph of Utah electrode.
electrode.[4] (b) Various configurations of the Michigan type
electrodes.[5]

3

Figure 2. The general structure of a Michigan type neural electrode.[6]
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Figure 3.. Structure of a micromachined single shank acute probe used in our research (16
recording sites, model: A1×16
A1×16-5mm-100-177-A16,
A16, NeuroNexus Technologies, Inc.)[7]
Inc.)

5

1.1.2 Tissue response to neural electrodes
Neural electrodes often fail to function reliably in clinically relevant chronic
settings. One of the proposed leading causes to such failure is foreign body response in
the central nervous system (CNS), resulting in an encapsulation layer referred to as the
“glial scar” and accompanied by loss of healthy neurons around the implants (Figure
4).[8-10]
The glial scar is formed as a result of activation of astrocytes and microglia. It
encapsulates the electrode as a physical barrier. It has several adverse effects toward
normal functioning of the implant. Firstly, this physical barrier is an insulating material
between the electrode and nearby neurons. The electrical interaction between brain and
machine is thus significantly compromised. Secondly, the tight glial scar takes up the
immediate room around the electrode, keeping neurons away from the interface.
Neuronal death is another phenomenon that has been considered causing
malfunction of the neural electrode. Neurons are challenged with a variety of toxic
environment such as oxidative stress after implantation of the neural electrode. Reactive
nitrogen species (RNS) and reactive oxygen species (ROS) are classes of free radicals
and related molecules that are capable of exerting oxidative stress on cells when
produced in excess. Nitric oxide (NO), a simple yet highly versatile molecule, is a type of
RNS/ROS frequently studied and involved in a wide range of physiological as well as
pathophysiological mechanisms. In response to injury, the production of NO can
overpower the endogenous antioxidants, leading to oxidative stress and cellular damage.
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Figure 4. Schematic of brain tissue response to an implanted electrode characterized at
the cellular level.[11]
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Reactive astrocytes and activated microglia have the capacity to generate NO, and
the production can be induced by pro-inflammatory cytokines such as interlukin (IL-1)
and tissue necrosis factor (TNF-α). NO is a ubiquitous second messenger[12] that
diffuses freely across cell boundaries and can damage neurons by potentiating glutamate
excitotoxicity.[13]
1.1.3 Methods to improve biocompatibility of neural electrodes
Improvements on electrode design[14-16] and manipulation of bioactive
molecules[17-24] through the tethering and/or controlled release of bioactive molecules
from the surface are the two main strategies to reduce the aforementioned tissue response.
Advances in electrode designs include not only microfabrication of electrodes with new
configurations[25], but also the development of novel polymers at the interface of
biology[26, 27], and bioinspired, mechanically dynamic polymers to replace currently
used stiff silicon materials[28]. Standard wound healing suppression and immunesuppression techniques are options for minimizing the initial immune response and even
the formation of a glial scar.[8] The available methods of using glucocorticoids and other
therapeutics to reduce the inflammatory response include systemic administration,[20,
29] localized delivery from coatings deposited on the electrode surface,[30] and direct
surface immobilization[11]. However, none of these approaches are ideal. For example,
systemic administration of drugs may cause serious side effects, including myopathy and
diabetes, and the presence of the blood-brain-barrier (BBB) adds extra hurdles for
systemic drug delivery to the CNS.[8, 31-33] Concerns associated with localized delivery
of therapeutics from surface coatings include the fine balance between drug loading

8

capacity and the conductivity of electrode (i.e., potential increase in impedance by the
coating), difficulty in controlling drug release rate, and the duration of delivery.
Immobilization of bioactive molecules directly onto the surface of electrodes could
provide a device with an intrinsically anti-inflammatory surface, but it is still restricted by
limited potency as the effect is confined to cells in direct contact with the surface.
Although it is possible that this is a design strategy which can be implemented to control
the local material-tissue interface while allowing other activated immune cells to
participate in local wound healing to “clean” up debris caused by electrode implantation,
this hypothesis needs to be confirmed.
A potential solution to pharmacologically manage the tissue response to
implanted electrodes is to enable self-regulated drug release based on the severity of
tissue response, without interfering with the electrical properties of the electrode.
Additionally, many studies have used localized release of anti-inflammatory
agents to control the inflammation against MEAs,[30, 34-37] but few reports have
addressed direct protection of cells from oxidative stress. We hypothesized that
protecting cells from the injurious oxidative stress could benefit the communication
between MEAs and healthy neurons. Astrocytes are one type of glial cells in the brain
supportive of neuron functions. It has been shown that astrocytes can protect neurons
from oxidant hydrogen peroxide toxicity.[38, 39] Therefore, we suggest that it is rational
to shield astrocytes and neurons from oxidative stress associated with implantable MEAs.
Such an approach could potentially lead to better survival of neurons that are vital for
long-term MEAs functions.
9

1.2 Layer-by-Layer (LBL)
Layer-by-layer (LBL) assembly technique is a versatile method for surface
modification. Traditionally, species with opposite charges are adsorbed alternately to a
surface, resulting in the formation of thin films with thickness ranging from nanoscale to
microscale (Figure 5).[40-42] On the one hand, the fundamental underlying mechanisms
such as the physicochemical aspects are a continuing research area. On the other hand,
LBL has been recently studied for applications in a range of fields, including biological
applications such as biomimetics, biosensors, drug delivery, protein and cell adhesion,
mediation of cellular functions, and implantable materials.[43]
Though the LBL technique has been most widely applied to charged molecules,
non-electrostatic forces, such as hydrogen bonding, have been recognized as an
alternative mechanism for film growth.[44-53] The common hydrogen bonding accepter
polymers include poly(N-vinylpyrrolidone) (PNVP), poly(acrylamide) (PAAM) and
poly(ethylene oxide) (PEO), and the hydrogen bonding donor polymers include
polyaniline, poly(acrylic acid) (PAA), and poly(methacrylic acid) (PMAA).[54] Tannic
acid (TA), a water soluble natural polyphenol has also been reported as hydrogen
bonding donor.[55, 56]
In addition to sharing the advantages of conventional electrostatic-based LBL
method, the multilayered-films constructed through hydrogen bonding could undergo
dissociation upon pH change, which could serve as smart coatings on implants.
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Figure 5.. Schematic of the LBL assembly process.
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from neural electrodes.[45] To overcome this issue, we propose to build a temporary
drug-containing coating on the electrodes using hydrogen bonding based LBL assembly.
Upon insertion into the tissue, the layers will quickly disintegrate under physiological pH,
revealing the underlying electrode surface and thereby eliminating the concern of
coating-induced loss of electrode functions.

1.3 Polymeric Therapeutics (Prodrug)
Polymer-drug conjugation (Figure 6) is a well-known and widely exploited
technique that is useful to improve therapeutic properties of peptides, proteins, small
molecules or oligonucleotides.[57-61] Polymer-conjugated drugs, sometimes referred to
as polymeric therapeutics or prodrugs, generally exhibit prolonged half-life,[62] higher
stability, improved water solubility,[63] lower immunogenicity and antigenicity,[64] and
can be designed to allow specific targeting to tissues or cells.[65] Besides the above
advantages, in this dissertation, polymeric therapeutics are selected to be compatible with
the LBL surface modification method to improve performance of the chronic neural
electrode.
A wide variety of polymers have been explored for prodrug synthesis. These
include synthetic polymers such as N-(2-hydroxypropyl) methacryl-amide copolymer
(HPMA),

polyglutamic

acid

(PGA),

poly(ethylene

glycol)

(PEG),

poly(N-

vinylpyrrolidone) (PNVP), and poly(ethyleneimine) (PEI). Examples of natural polymers
used for this application include dextran, pullulan, chitosan, hyaluronic acid and many
others.[66]
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Figure 6. Features of polymeric therapeutics.
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In this dissertation, two types of prodrugs were prepared, one anti-inflammatory
for glial scar prevention and the other anti-oxidative for direct neural protection. The antiinflammatory prodrug was built from PNVP. PNVP is a hydrophilic synthetic polymer
generally known for its biocompatibility and non-antigenicity, and is considered safe for
biological experiments.[67] Soluble PNVP is one of the most versatile and widely used
pharmaceutical auxiliaries and topical disinfectants.[68] However, lack of common
functional groups in PNVP has limited its further applications such as conjugation with
other biological therapeutics. I proposed to overcome such a limitation by functionalizing
PNVP with carboxylic acid groups to allow the synthesis of anti-inflammatory prodrugs.
For the anti-oxidant prodrugs, I prepared a polymerizable monomer derived from an antioxidant and copolymerized it with a biocompatible acrylate monomer with functionalities
amenable for LBL assembly.

1.4 Stimuli-Responsive Polymers
1.4.1 Thermo-responsive polymers
Thermo-responsive polymers are among the most intensively investigated smart
materials in biomedical fields.[69-71] A key characteristic of these polymers is that they
display a lower critical solution temperature (LCST). At temperatures below the LCST,
these polymers are soluble in water. Upon raising temperatures above the LCST, such
polymers will undergo a conformational transition from loose solvated coils to compact
dehydrated globules, collapse and become insoluble in water.[72] Such a phase
separation process occurs by either nucleation and growth, or spinodal decomposition
(Figure 7).
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Figure 7. An example of phase diagram for polymers with LCST behaviors.[73]
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Nucleation and growth are associated with metastability. Spinodal decomposition, on the
other hand, refers to phase separation under conditions in which the energy barrier is
negligible, so no activation energy is required. The spinodal line is constructed from the
points where,
∅

=0

1

where G is the free energy, Φ is the composition.
The binodal curve is related to the equilibrium phase boundary between the single
phase and the phase separated region. In a binary system, this is related to the chemical
potentials of an individual component being equal in both phases as expressed by the
following relationships:
∆
∆

=∆
=∆

2
3

where µ is the chemical potential, 1,2 represent the two components and a,b
represent the phases.[73, 74] If the temperature of a mixture is raised above the LCST,
that component undergoes thermally induced phase separation by either nucleation and
growth or by spinodal decomposition (SD). The minimum value occurring at the
intersection of the binodal line and spinodal line is the LCST. Whether nucleation and
growth or SD occurs depends on how phase boundary is crossed. If the binodal line is
crossed, the component becomes thermodynamically metastable. Under this scenario,
phase separation is favorable but only achieved by nucleation and growth. If instead the
spinodal line is crossed, SD will occur. The transition points between phase-separation
and homogenous solution are therefore dependent on how temperature is changed.
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Hysteresis of the reversible transition is related to the difference between spinodal and
binodal curves. Note that phase separation is visually accompanied by an increase in
turbidity or cloudiness of a solution. The cloud point is the temperature where the
solution starts to become cloudy. And LCST is the cloud point at the critical composition.
For simplicity, an experimentally determined cloud point is often reported rather than an
LCST.
While poly(N-isopropylacrylamide) (PNIPAAm) has dominated as the most welldocumented thermo-responsive polymer, there are growing interests on other types of
polymers with LCST behaviors, such as poly(vinyl methyl ether) (PVME)[75], poly(2oxazoline)[76], and poly(N-vinyl-2-caprolactam) (PVCL)[77].
PVCL is water soluble and biocompatible, with LCST in the vicinity of
physiological temperature.[78] Its good biocompatibility is attributed to the fact that the
amide group in PVCL is directly bonded to the hydrophobic backbone, thus its hydrolysis
will not result in the production of cytotoxic small amide compounds.[79] The unique
temperature dependent behavior of PVCL has been employed to prepare thermoresponsive microgels for a variety of applications, including thermal sensitive drug
delivery[80] and template for oxidative polymerization of pyrrole.[81, 82] It also has
been used to stabilize proteases.[83] Furthermore, thermo-sensitive PVCL was recently
employed by Zhuk and coworkers[84] for constructing pH responsive multilayers, which
can be delaminated at high pH values.
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1.4.2 Dual responsive polymers
In conjunction with temperature, other stimuli including pH have been used in
developing dual responsive polymers. For example, researchers have copolymerized
NIPAAm with negatively charged carboxylic acid containing monomers such as alkyl
acrylic acid,[85-88] N-acryloylavaline,[89] and succinic anhydride modified dextran[90].
Alternatively, monomers containing positively charged amino groups have also been
commonly polymerized with NIPAAm, such as N,N-dimethylaminoethyl methacrylate
(DMAEMA),[91] L-lysine,[92] and trans-4-hydroxyl-L-proline.[93] A few other
polymers, which are not based on NIPAAm, have been reported with dual-responsive
properties, such as

copolymers of di(ethylene glycol) methyl ether methacrylate

(MEO2MA) with either methacrylic acid (MAA) or DMAEMA,[94] homopolymer of
poly(N-ethylpyrrolidine methacrylate),[95] graft copolymers containing PMAA backbone
and oligo(2-ethyl-2-oxazoline) (OEtOx) side chains,[96] and poly(amidoamine)
dendronized poly(2-hydroxylethyl) methacrylate[97]. These dual responsive polymers
have been explored in applications including control of micelle structures,[89, 91, 93]
advanced drug delivery systems,[85, 88, 98] fabrication of dual functional nanofluidic
devices,[86] and modification of gold nanoparticles.[90]
Based on the LCST behaviors of PVCL polymers, I designed its functional
derivative with pH-dependent LCST behaviors for smart drug delivery. The goal is to use
the smart polymer as an alternative to enable tissue response specific release of antiinflammatory drugs.
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1.5 Polymer chain conformation [73, 99]
The freely jointed chain model is the simplest mathematical description of a
polymer chain. In assumption, a single polymer chain has n bonds, each of length l,
joined in a linear sequence with no restrictions on the angles between successive bonds.
In this model, the mean-square end-to-end distance (

) is given by the following

equation:
=

4

However, it underestimates the real end-to-end distance of a polymer chain,
omitting factors such as bond angle, conformation angle, excluded volume, steric
hindrances, etc. The correction is represented by a constant, characteristic ratio C∞ by the
following equation:
R = C" nl

5

The end-to-end distance is difficult to measure. Instead, the radius of gyration, Rg,
is often used since this quantity can be measured by a light scattering technique. The
radius of gyration is the average distance from the center of the gravity to the chain
segment. The mean-square value of the radius of gyration can be related to the meansquare value of the end-to-end distance by the following equation:
R$ = % R =

&' ()
%

6

In a crude approximation, each linear polymer chain occupies a space of a sphere
with the dimension of Rg, At low concentrations, these spheres are separated from each
other. As the concentration increases, they become congested and eventually touch each
other. At the overlap concentration (c*), the whole volume of the solution is packed with
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these spheres. The overlap concentration of the solution is given by the following
equation:
c∗ =

+,

-./0 132

7

where M is the molecular weight of the polymer, and NA is the Avogadro’s
number.
When polymer concentration is below c*, the solution is considered dilute. The
polymer chains are separated from each other and behave more or less independently.
The chain interacts primarily with the solvent molecules. The solution is close to an ideal
solution. The situation is different at concentrations above c*. The solution in this regime
is considered semidilute. The polymer chains are overlapped and entangled. Their
mobility is greatly reduced compared with the chains in dilute solutions. The
thermodynamic properties of the semidilute solutions are greatly different from those of
an ideal solution extrapolated to the same concentration. At an even higher concentration,
the solution enters the concentrated regime in which each segment of the polymer chain
does not have a sufficient space available.
This dissertation studied the molecular behaviors in the LBL assembly by
examining polymer chain dimension in aqueous solutions. The assembly process at the
molecular level was proposed by correlating thickness of the layer with the polymer
chain conformation information.

20

1.6 Dissertation Structure
The objective of this dissertation research is to develop polymer mediated
therapeutic interventions to help improve long-term performance of implantable neural
electrodes. Failure of neural electrodes has been mainly attributed to glial scar formation
and loss of neurons around the implant. To address each of the causes, I have tailor
designed polymer based therapeutic interventions and studied their application toward
neural electrodes. Furthermore, a pilot study was carried out to synthesize a dualresponsive biocompatible polymer intended for smart drug delivery at the interface. The
content of this dissertation is schematically shown in Figure 8:
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Figure 88. Overview of the dissertation research.
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Chapter 2
Synthesis and Characterization of Glucocorticoid Functionalized
Poly(N-vinyl pyrrolidone): A Versatile Prodrug for Neural Interface
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An article presenting part of the results in this chapter has been published on
Biomacromolecules. [Cao Y, He W. Synthesis and Characterization of Glucocorticoid
Functionalized Poly(N-vinyl pyrrolidone): A Versatile Prodrug for Neural Interface.
Biomacromolecules 2010;11:1298-307.] The first author (Yu Cao) finished all of the
experiments in this study. The corresponding author (Dr. Wei He) is advisor of Yu Cao
and financially supported this work.

2.1 Introduction
Chronically implanted recording electrode arrays have the potential to improve
the quality of life of patients suffering from partial or full paralysis. However, they often
fail to function reliably in clinically relevant chronic settings. A potential solution to
pharmacologically manage the tissue response to implanted electrodes is to enable selfregulated drug release based on the severity of tissue response, without interfering with
the electrical properties of the electrode. Integrating the surface modification method
based on LBL assembly and stimuli-responsive drug conjugates, one could accomplish
the proposed ‘smart’ and effective drug delivery at the neural interface (Figure 9).
The multilayered-films constructed through hydrogen bonding mediated LBL
assembly could undergo dissociation upon pH change, which could serve in the
application of smart coatings and be particularly attractive to biosensors such as neural
electrodes, where preserving electrical properties significantly limits the characteristics of
any coating deposited on the surface.[45]
Specifically, the electrode surface could serve as a temporary support for the
drug-containing LBL multilayered film. Upon insertion into the tissue, the layers will
24

Figure 9. Surface modification of neural electrode with LBL assembly and drug release
responsive to tissue reaction.

25

quickly disintegrate under physiological pH, revealing the original electrode surface and
eliminating the concern of coating-induced loss of electrode function (Figure 9).
To directly link drug release with the extent of tissue response, the molecular
characteristics of tissue response can be used as the trigger. Tissue acidosis, a decrease of
extracellular pH of the tissue, has been observed after brain injury by many
researchers.[100-103] Such a decrease in pH is also related to frustrated phagocytosis, a
process that involves macrophages actively attacking non-phargocytosable surfaces,
leading to the accumulation of degradative substances such as acid at the cell-biomaterial
interface.[62, 104] Therefore, a drug conjugate with a pH sensitive moiety will
potentially enable tissue response regulated drug release. Prodrug is useful to improve
therapeutic properties of peptides, proteins, small molecules or oligonucleotides. In order
to realize tissue acidosis controlled drug release, one could easily engineer a pH-sensitive
trigger into the molecular structure of the prodrug. Hydrazone is one of the common acid
labile linkages used in prodrug applications.[105, 106] It is relatively stable at
physiological pH (7.4), but hydrolyzes at acidic pH normally found at pathological sites
(below 6.0) such as tumors,[107, 108] infarcts,[109] and inflamed tissue.[110] Therefore,
hydrazone bonding was used in this study to form prodrug of anti-inflammatory
glucocorticoids.
The other desired feature of the prodrug is its ability to participate in the LBL
process based on hydrogen bonding. Thus a functional derivative of the hydrogen bond
acceptor PNVP was used for drug conjugation. Several methods have been explored to
introduce functional groups such as carboxylic acid and amine onto either the pendant
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chain or polymer end.[111-115] The pendant carboxyl groups of PNVP derivative can be
used for drug conjugation while the repeating lactam ring provides hydrogen bond
accepting function in the LBL process. PNVP is a hydrophilic synthetic polymer
generally known for its biocompatibility and non-antigenicity, and is considered safe for
biological experiments.[67] Soluble PNVP is one of the most versatile and widely used
pharmaceutical auxiliaries and topical disinfectants.[68] However, lack of common
functional groups in PNVP limits its further applications such as conjugation with other
biological therapeutics.
In this chapter, I have synthesized a glucocorticoid functionalized PNVP prodrug
that displayed responsive drug release in vitro under conditions mimicking inflammation.
The feasibility of transporting the prodrug to the neural interface using the LBL method
without permanently encapsulating the electrode was evaluated. The bioactivity of the
prodrug and its released products was also examined in terms of anti-inflammatory
potency and neurotoxicity. This newly developed drug delivery system could potentially
resolve the dilemma between increasing drug loading capacity and maintaining the
conductivity of electrode. Furthermore, it enables direct regulation of drug release by the
tissue response, thus allowing more effective and active therapeutic treatment at the
neural interface.

2.2 Experimental Section
2.2.1 Materials
Diisopropylamine, azobisisobutyronitrile (AIBN), di-tert-butyl dicarbonate, Nethyl-N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), prednisolone, and
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polyethyleneimine (PEI) with Mn = 1,800 g/mol were obtained from Sigma-Aldrich.
Tetrahydrofuran (THF), N-vinyl-2-pyrrolidone (NVP), N,N’-dimethylformamide (DMF),
n-butyllithium, tert-butyl carbazate (TBC) and trifluoroacetic acid (TFA) were obtained
from Acros. Deuterated dimethyl sulfoxide, chloroform, and water were obtained from
Cambridge Isotope Laboratories, Inc. Polyacrylic acid (PAA) with Mw = 450,000 g/mol
was purchased from Polysciences, Inc. Hexanes, ethyl acetate, dichloromethane (DCM)
and quartz slides were purchased from Fisher Scientific. Dialysis membrane (MWCO =
500 Da) was obtained from Spectrum Lab, Inc. All reagents were used as received unless
otherwise noted.
2.2.2 Characterization
1

H NMR (300 MHz) spectra were recorded on a Varian Mercury 300 NMR

spectrometer. Gel permeation chromatography (GPC) was performed at room
temperature using PL-GPC 50 plus (an integrated GPC/SEC system from Polymer
Laboratories, Inc.) with a refractive index detector. DMF was used as the carrier solvent
at a flow rate of 1.0 mL/min. Standard monodisperse polystyrenes (Polymer
Laboratories) were used for calibration. UV-vis spectra were measured using a UV-vis
spectrometer (Biomate 5 from Thermospectronic). Ellipsometric measurements were
performed on dry films in air using an L0116S Stokes ellipsometer (Gaertner scientific
corporation) with He/Ne laser (632 nm) illumination at a 70° angle of incidence. A
refractive index of 1.465 for the dry film was assumed.
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2.2.3 Prodrug synthesis
Synthesis of carboxylated NVP copolymer (COOH-PNVP). Monomer of 3-(tertbutoxycarbonyl)-N-vinyl-2-pyrrolidone

(TBNVP)

was

synthesized

as

described

previously.[114] NVP (5.328 g, 1.6 mol/L), TBNVP (2.532 g, 0.4 mol/L), AIBN (0.148
g, 0.03 mol/L) and freshly distilled THF (30 mL) were added into a 250 mL flask, and
subjected to three freeze-thaw cycles to remove oxygen. Polymerization reaction took
place at 65 °C for 22 h. The polymer was then precipitated in hexane, redissolved in THF
and reprecipitated in hexane for purification. The obtained polymer (PTBNcoN) was
dried in a vacuum oven at 55 °C overnight (6.555 g, 83% yield, Mw: 16,900 g/mol). The
carboxyl groups (-COOH) were recovered by removing the t-BOC protecting groups
using TFA. Briefly, PTBNcoN (6.259 g, 9.55 mmol t-BOC) was dissolved in DCM (15
mL) followed by the addition of 15 mL TFA. After reacting for 4 h, the polymer was
recovered by solvent evaporation and dialysis against deionized water overnight and
lyophilization. The yield was 5.05 g (80%).
Synthesis of NVP-hydrazide copolymer (PNVP-NH-NH2). COOH-PNVP (3.568 g,
5.9 mmol COOH) and TBC (0.808 g, 5.9 mmol) was dissolved in 25 mL of ultrapure
water. Aqueous solution of EDC (1.17 g, 5.9 mmol) was then added dropwise. The
reaction mixture was stirred for 24 h at room temperature. Unreacted TBC and EDC were
removed by dialysis against deionized water extensively. The product, t-BOC protected
NVP-hydrazide copolymer (PNVP-NH-NH-BOC) was obtained by lyophilization (3.584
g, 76%). To remove the BOC protecting groups, TFA was used. Briefly, PNVP-NH-NHBOC (1.171 g) was dissolved in DCM (10 mL) and TFA was added (10 mL). After 4 h of
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reaction at room temperature, the solvent was evaporated, and the purified PNVPhydrazide copolymer (PNVP-NH-NH2) was obtained by dialysis against deionized water
extensively and lyophilization. The yield was 1.058 g (89%).
Synthesis of NVP-glucocorticoid prodrug (PNVP-Pred). PNVP-NH-NH2 (0.712
g) was mixed with the glucocorticoid drug prednisolone (1.204 g) in DMF and 50 µL of
acetic acid was added as a catalyst for the reaction. The solution was kept stirring for 24
h. The mixture was precipitated in water to remove unreacted prednisolone (limited water
solubility 142 mg/L[116]) while the prodrug remained in the aqueous solution. The
obtained solution was dialyzed against deionized water extensively and lyophilized to
obtain prodrug (0.410 g, 38%).
2.2.4 pH sensitive drug release
Prodrug (10 mg/mL) was dissolved in either an acetate buffer (0.15 M, pH 5.0), or
a phosphate buffer (0.15 M, pH 7.4). One millimeter of prodrug solution was then loaded
to a dialysis tube (MWCO 500 Da) and incubated in 20 mL of corresponding buffer at 37
°C. At selected time intervals, the solution outside the dialysis membrane (60 µL) was
withdrawn for high-performance liquid chromatography (HPLC) analysis. A Thermo
Scientific Finnigan HPLC system coupled with dual wavelength detector was used for the
drug release study. A reverse phase C18 (Waters Sysmmetry, 4.6 × 150 mm, 5 µm) was
used for the analysis with acetonitrile/water as the mobile phase. The flow rate was set
constant at 1.0 mL/min. The UV detection wavelength was at 240 nm. The sample
injection volume was 20 µL for all evaluations. A linear external prednisolone calibration
curve was established. The amount of prednisolone released was quantified by converting
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the UV absorbance at 240 nm against the standard calibration curve. All drug release data
are presented as the amount of free prednisolone relative to the total prednisolone content
in the prodrug conjugate.
2.2.5 LBL assembly with PNVP prodrug (PNVP-Pred)
The self-assembled films were prepared either on quartz slides or silicon
substrates with a 100 nm thick oxide layer (University Wafer), depending on the specific
characterization methods used. Before layer deposition, the silicon wafers were cut into
small squares (1 x 1 cm). Both substrates were cleaned in a boiling piranha solution (3:1
concentrated H2SO4 : 30% H2O2 v:v; piranha solution reacts violently with organics and
should be handled with extreme caution) for 30 min, washed with copious amount of
water and dried under nitrogen. The substrates were first immersed in a PEI solution (1.5
mg/mL, pH = 7) for 30 min, followed by rinsing in water for 1 min. The PAA/prodrug
multilayers were then assembled by alternating immersion of the substrates in solutions
of PAA (0.5 mg/mL, pH = 3) and prodrug (0.5 mg/mL, pH = 3) for 5 min, respectively.
Between each step, the excess polymer was removed by rinsing the substrates with HCl
solution (pH = 3) for 1 min. All solutions were prepared using ultrapure water (Milli Qplus system, Millipore) with a resistivity of 18.2 MΩ·cm. The assembly process was
monitored with UV-vis spectrometer and ellipsometry. The coated substrates were
immersed in phosphate buffered saline (PBS, pH = 7.4) for 1 h, and subsequent
ellipsometric measurements were carried out to characterize layer desorption.
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2.2.6 Bioactivity of prodrug and its released products
In vitro anti-inflammatory study of prodrug. A subclone of RAW264.7 murine
macrophages (kindly provided by Dr. Tim Sparer of the University of Tennessee) were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS, Invitrogen), 1% L-glutamine and 1% penicillin/streptomycin. Cells
were cultured at 37 °C, 5% CO2 and 95% relative humidity. For anti-inflammatory study,
cells were seeded in 48-well tissue culture plates at a density of 1.0 × 105 cells/well and
allowed to attach overnight. Culture medium was then aspirated and replaced with fresh
medium. Cells were stimulated to generate nitric oxide (NO), a potent inflammatory
mediator, with 100 ng/mL of lipopolysaccharide (LPS) (Sigma), and treated with solution
of prednisolone, prodrug or precursor polymer (PNVP-NH-NH2) (concentration
equivalent to 1.1 µM prednisolone) simultaneously. All treatments were done in
triplicate. After 24 h of incubation, the amount of stable nitrite accumulated in the culture
medium, the end product of NO production, was determined by Griess reagent
(Promega).[116]
In vitro anti-inflammatory study of products from prodrug release. Prodrug
solution was prepared with either a PBS buffer (pH = 7.4) or an acetate buffer (pH = 5.0),
and incubated at 37 °C. At various time points (day 1 and day 10), an aliquot of solution
was withdrawn and stored at -20 °C. Prodrug solutions were also collected before
incubation and noted as day 0 samples. Macrophages were cultured and activated as
described in the previous section, and treated using the incubated prodrug solutions
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collected at day 0, 1, and 10, respectively. NO production was analyzed using the Griess
assay.
The results for Griess assay study were expressed as percentage to the untreated
LPS stimulated control, and analyzed by analysis of variance (ANOVA) using a SAS
software. Least squares means were compared by Least Significant Difference (LSD)
test. For all analyses, significance was assigned for p < 0.05. All cell culture studies were
repeated to account for biological variance.
Primary cortical neuron culture. Cortical neurons were obtained from 9-day-old
chicken embryos. Forebrains of the embryo were dissected, minced into small pieces, and
enzymatically dissociated with 0.25% trypsin in PBS for 20 min at 37 °C, followed by
inactivation with medium containing 10% FBS (Invitrogen). A cell pellet was obtained
after a brief centrifugation, and mechanical trituration using a fire-polished Pasteur pipet
was applied to further dissociate the cells. Cells were then preplated on a collagen-coated
Petri dish and incubated for 1 h at 37 °C in a 5% CO2 atmosphere. This process has been
reported to provide culture with 97% of neuron composition.[117] Purified neuronal cells
were collected and resuspended for cell culture.
In vitro cytotoxicity study. The cytotoxicity of the prodrug and its polymer
precursor PNVP-NH-NH2 towards neurons was determined. Cortical neurons were
seeded into wells of 24-well tissue culture plates precoated with Laminin at a density of
5.0 × 104 cells/cm2 and cultured in DMEM supplemented with 10% FBS, 1%
penicillin/streptomycin, and 1% L-glutamine at 37 °C in a 5% CO2 atmosphere for 2
days. Cell culture medium was then aspirated and replaced with fresh medium
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supplemented with either prodrug or PNVP-NH-NH2 (100 µM, equivalent to
prednisolone). Cells were incubated for another 2 days and cell viability was determined
using a WST-1 assay (Roche) according to the manufacturer’s instruction. Cell viability
was calculated by normalizing the absorbance to that of the controls. Furthermore, a
qualitative morphological study was performed simultaneously. Briefly, at the end of
culture, cells were live stained with 0.05 v/v Calcein AM (Invitrogen) solution in PBS
and incubated at 37 °C in a 5% CO2 atmosphere for 30 min. Samples were rinsed twice
with PBS before and after fluorescence staining. Fluorescent images were collected using
a 10× objective lens on a confocal microscope (Leica SP2, Germany).
2.2.7 Prodrug diffusion
Synthesis of fluorescent prodrug analog (FPNVP). The reaction is modified from
a previous report.[118] PNVP-NH-NH2 (0.03 g) was dissolved in sodium carbonate
buffer (16 mL) at pH 9. Fluorescein isothiocyanate (FITC) in anhydrous DMSO (0.15
mL, 1 mg/mL) was added to the above PNVP-NH-NH2 solution. The solution was kept
stirring for 10 h. The mixture was quenched by the addition of ammonium chloride (16
mg) to a final concentration of 50 mM. The obtained solution was dialyzed against
deionized water extensively in dark and lyophilized to obtain FPNVP (0.012 g, 40%).
Diffusion experiment. The Si substrates were firstly coated with 8 bilayers of
FPNVP and PAA using the LBL method mentioned in section 2.2.5. A 0.6 wt% SeaKem
agarose solution was poured onto a Si wafer with 8 bilayers of (FPNVP-PAA). Gel was
formed within 5 minutes. Then 1 mL PBS was added on top of the gel. The system was
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kept in dark overnight at 37 °C. Then fluorescent images were captured. The software of
Image J was used to analyze the fluorescent pictures to obtain quantitative data.

2.3 Results and Discussion
2.3.1 Prodrug synthesis and characterization
In this work, the synthesized prodrug was based on PNVP and anti-inflammatory
glucocorticoid drug of prednisolone. The prodrug was prepared following procedures
outlined in Figure 10. The conjugation scheme can be easily translated to other members
of the glucocorticoid family, such as dexamethasone and methylprednisolone. Due to the
lack of reactive groups for drug conjugation in monomer (NVP), it is common to
copolymerize NVP with other functional vinyl monomers. However, reactivity of NVP
differs greatly from those of other monomers, which results in compositional shift from
feeding ratio. Therefore, a derivative of NVP was used to copolymerize with NVP in
preparing functional PNVP. The derivative, TBNVP, bears a protected carboxyl group at
the α-position of NVP, and is expected to show similar radical reactivity with NVP due to
the structure similarity between the two monomers. As shown in a, integration of 3CH2
and 7CH3 revealed that the molar ratio of TBNVP in the prepared copolymer was 18
mol%, suggesting good agreement with the monomer feeding ratio of 20 mol%. Thus,
copolymerization of TBNVP and NVP monomers allows controlled introduction of
functional groups into the polymer with little compositional drift.
In order to render the prodrug susceptible to tissue acidosis, an acid labile
hydrazone group was used to conjugate prednisolone to the functional PNVP.
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Figure 10. Glucocorticoid prodrug synthesis via conjugation of prednisolone onto
functionalized poly(N-vinyl pyrrolidone).
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Briefly, the carboxyl group at the α-position of PNVP was exposed by acid removal of
the t-BOC protecting group, and subsequently converted into hydrazide groups by
reacting with tert-butyl carbazate followed by acid deprotection. The use of TFA for
deprotection of t-BOC groups is highly efficient as reported in the literature[119] and
further confirmed in this study by the disappearance of the characteristic t-butyl peak at
δ1.33 in the NMR spectra (Figure 11b and d). Conversion of the functional groups can be
obtained using integrations of 3CH2 and 7CH3. Briefly, PTBNcoN was fully converted to
COOH-PNVP. Subsequently, 88.9% of the -COOH groups were converted to BOChydrazide, followed by 100% conversion to unprotected hydrazide. This means that the
composition of the copolymer prior to drug conjugation was 82 mol% of NVP, 16 mol%
of NVP-NH-NH2, and 2 mol% of NVP-COOH. Prednisolone was conjugated onto the
copolymer through formation of a hydrazone bond between the pendant hydrazide group
of the copolymer and the ketone carbonyl group on prednisolone. Because prednisolone
has poor solubility in D2O, d8-DMSO was chosen as the NMR solvent for comparison
between free drug and prodrug, even though the prodrug has good water solubility. As
shown from Figure 12, the 1H-NMR spectrum of prodrug presents signals between δ4.0
and δ7.6, attributed to protons of the prednisolone moieties. It indicates success of drug
conjugation to the copolymer. The degree of prednisolone conjugation to the polymer
was determined by UV absorbance spectroscopy analysis of the prodrug solution. Figure
13 showed UV spectra of 0.1 mg/mL solutions of prednisolone, prodrug, and its polymer
precursor PNVP-NH-NH2.
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Figure 11. 1H-NMR spectra of (a) PTBNcoN, (b) COOH-PNVP, (c) PNVP-NH-NHBOC and (d) PNVP-NH-NH2 in D2O.
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Figure 12. 1H-NMR spectra of (a) prodrug PNVP-pred and (b) free drug prednisolone in
d8-DMSO.
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Figure 13. UV spectra of 0.1 mg/mL aqueous solution of (a) prodrug PNVP-pred, (b) free
drug prednisolone, and (c) precursor polymer PNVP-NH-NH2.
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The prodrug and prednisolone share the characteristic peak at 247 nm. Prednisolone
solutions of various concentrations were prepared and the absorbance at 247 nm was
measured to generate a calibration curve for prednisolone content calculation. The
amount of prednisolone conjugated to the polymer was 160 mg/g prodrug, determined by
comparison of UV absorbance spectrum of prodrug against the prednisolone calibration
curve generated in our lab.[120, 121] Composition of NVP-pred in the prodrug was
calculated as 6 mol%, indicating that 60% of the hydrazide groups were consumed for the
conjugation. The polydispersity of the prodrug was 3.84 as characterized by GPC.
Although only one degree of conjugation was studied in the present work as a proof-ofconcept, the level of functionalization and drug loading capacity can be easily tuned by
varying the initial copolymer composition between NVP and TBNVP. To characterize
the release profile of the synthesized prodrug bearing acid-labile functional groups, two
release conditions were used. One condition is a pH 7.4 buffer representing normal tissue
and the other condition is a pH 5.0 buffer simulating severely inflamed tissue.[122] As
expected, the hydrazone-containing prodrug demonstrated pH-sensitive drug release
behavior. Within 25 days, the percentage of prednisolone released from the prodrug was
always higher at acidic pH than at physiological pH (Figure 14).
The faster drug release rate under acidic condition is characteristic of the
hydrazone bond, as its hydrolysis rate has been shown to be accelerated in the presence of
an acid.[106, 123] This result suggests that more anti-inflammatory drugs will be released
in case of tissue acidosis, therefore potentially enabling more effective and active
pharmacological management of inflammatory tissue response at the implant interface.
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Figure 14. In vitro cumulative release of prednisolone from prodrug at different pH levels
up to 25 days. Standard deviation is less than 5% of the mean value (n=3).
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There are two carbonyl groups at positions 3 and 20 in the prednisolone structure,
as shown in Figure 10. A question related to the reaction mechanism is that which group
reacts with PNVP-NH-NH2 to form the prodrug. Inferred from the fact that no
crosslinking occurred during the reaction, it is possible that these two carbonyl groups
differ in reactivity. Because the carbonyl group attached to the six-membered ring
(position 3) is stabilized by the conjugated structure, I suggest that the other carbonyl
group is more reactive. Therefore, the carbonyl group attached to the five-membered ring
(position 20) is thought to be the reacting group in the prodrug synthesis step.
In order to directly identify which carbonyl group reacts with PNVP-NH-NH2,
control experiments could be designed. This study can also shed light on the crosslinking
concern caused by potential role of prednisolone as a crosslinker due to the presence of
two carbonyl groups. Control reactions designed using commercially available chemicals
are shown in Figure 15.
The reaction and workup procedures will be the same with that described in
section 2.2.3. NMR spectra will be collected to determine chemical structure of product
from reaction 1 and 2. Specifically, residual peaks from R1 or R2 will be screened to
prove if any reaction happened. There are four possible outcomes as show in Figure 15.
Out of these four outcomes, if b or c happens, it will be a clear indication of
which carbonyl group on prednisolone reacted with PNVP-NH-NH2. Result d is unlikely
because either reaction 1 or 2 should occur based on the results of the reaction between
PNVP-NH-NH2 and prednisolone.
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Possible outcomes from the control reactions:
Reaction 1 occurred

Reaction 1 not occurred

Reaction 2 occurred

a

b

Reaction 2 not occurred

c

d

Figure 15. Control reaction for illuminating the reactivity of the two carbonyl groups at
positions 3 and 20 in prednisolone.

44

If outcome a is observed, this will mean either carbonyl can react. Further control
reaction could be carried out by mixing an equal molar amount of R1 and R2. The amount
of R1 (or R2) will be kept in excess as compared to the amine group on PNVP-NH-NH2,
such as at a ratio of 3:1. Then the structure of final product could be determined. From
here, the reactivity of the two carbonyl groups can be finally confirmed.
2.3.2 Application of prodrug for LBL assembly
The approach of integrating prodrug within self-assembled multilayers has been
previously reported. Thierry and co-workers used a hyaluronan ester prodrug of
paclitaxel, a potent hydrophobic chemotherapeutic agent, as a polyanion to prepare
polyelectrolyte multilayers with a natural polyamine chitosan.[124] In their study, drug
release resulted from the hydrolysis of the ester bond and subsequent diffusion of
paclitaxel out of the film, while the multilayers remained stable throughout the release
study. In the present work, a less stable multilayered film was preferred considering the
application towards neural sensors such as electrodes. Therefore, the PNVP hydrazone
prodrug of prednisolone was used for LBL assembly based on hydrogen bonding. PAA
and PNVP could be deposited on a variety of substrates using the LBL technique through
the hydrogen bond between the carboxylic acid groups on PAA and carbonyl groups on
PNVP.[40, 45, 125] The stability of hydrogen-bonded PAA/PNVP multilayers is limited
to a particular pH range, and layer deconstruction usually occurs under physiological pH
(7.4).[126] Such pH-dependent stability is in fact advantageous for neural electrodes. As
mentioned earlier, there is a fine balance between effective coating-based localized
release of therapeutics and the electrical functionality of the neural electrodes. With this
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destructible hydrogen bonding interaction, the neural electrodes can serve as a temporary
support for film construction and transport the film to the tissue-electrode interface via
implantation. The physiological pH will then quickly release the film off the electrode
surface leading to an implanted bare electrode in the neural tissue surrounded by
molecular components of the disintegrated film (Figure 9). Those components can exert
therapeutic actions when needed if proper release triggers are engineered into the
molecular structure. Since prednisolone was conjugated via the pendant functional groups
of the PNVP, the prepared prodrug still contained the carbonyl groups, which can form
hydrogen bond with PAA. Using the LBL technique, hydrogen-bonded PAA/prodrug
multilayers were coated onto silicon substrates, a material commonly used in recording
neural electrodes. Ellipsometric measurements (Figure 16a) revealed that film growth
was a linear function of the number of PAA/prodrug bilayers deposited (for up to 8
bilayers), with an average bilayer thickness of 27 nm. This trend was also confirmed by
UV-vis spectrophotometry of the multilayered films on quartz substrates, as indicated in
Figure 16b. The absorbance peak at 193 nm originates from PNVP of the prodrug layer.
A linear increase of absorbance at 193 nm in relation to the number of bilayers was
observed, suggesting film growth of PAA and prodrug.[127]
To demonstrate that the PAA/prodrug multilayer film can be released from the
silicon surface in a physiological environment, the coated substrates were immersed in
PBS (pH = 7.4), and subsequent ellipsometric measurement confirmed the destruction of
the multilayer coating within 1 h.
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Figure 16. Assembly of LBL films. (a) Plot of ellipsometric film thickness versus the
number of PAA/prodrug bilayers deposited on a silicon substrate. (b) UV-vis absorption
spectra of multilayer films of PAA/prodrug after 2, 4, 6 and 8 bilayer depositions. Inset:
Absorbance at 193 nm (contribution from PNVP) versus number of assembled bilayers.
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The pH sensitivity of the hydrogen-bonded PAA/prodrug multilayer was
consistent with other reports.[45, 126] This pH sensitive prodrug containing coating
could be a simple yet effective approach to modify recording neural electrodes, in which
one could incorporate a sufficient amount of prodrug to aid in managing the host
response to the implanted electrode without the concern of sacrificing the electrical
property of the neural electrode.
Because of the versatility of the LBL technique, such a prodrug system can be
easily applied to other implantable sensors where a permanent, drug embedded coating
might compromise the sensing function of the device. It is worth mentioning that PEI was
used as the base layer to prime the surface for subsequent LBL process. Although toxicity
of PEI is a debatable concern for biological applications[128-130], only a minute amount
of PEI was present on the substrate (i.e., it has been reported less than 0.1 g/cm2 of PEI
deposited as a base layer for LBL[131]). Furthermore, toxicity of PEI depends on the
molecular weight, where 2 kDa PEI was nontoxic even at concentrations as high as 45
g/mL[132]. The PEI used in this study has a molecular weight of 1.8 kDa, and therefore,
it is not expected to exert significant adverse effects on neurons.
In this LBL assembly system of PAA/prodrug, PAA is chosen to facilitate
deposition of prodrug in the dissociable coating. Actually, other polymers with
carboxylic acid group could possibly substitute PAA. Therefore, polymers with good
biocompatibility could be tried, which will be further discussed in chapter IV.
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2.3.3 Bioactivity and biocompatibility of prodrug and its released products
The prodrug was designed for suppression of host inflammatory response towards
recording electrodes inserted in the CNS. Activation of microglia, the only resident
phagocytotic cells in the CNS, was observed following injury caused by electrode
implantation.[8, 133, 134] The activated microglia, also known as the brain macrophages,
continually produce various cytotoxic and neurotoxic factors.[8] It has been suggested
that inhibition of microglia activation is a potential strategy to reduce immune response
against the electrode.[11, 30] In addition to microglia, electrode implantation inevitably
damages the vasculature of the CNS, leading to extravasation of blood borne, monocytederived macrophages into the CNS tissue. These macrophages act in concert with
activated microglia to defend the CNS against the non-self electrode. Because of the
functional similarity, the present study selected the readily available monocyte-derived
macrophages instead of isolating primary microglia from neonatal rats to examine the
anti-inflammatory effect of the prodrug and its released products. Specifically, the wellestablished RAW264.7 murine macrophages were used. RAW264.7 murine macrophages
are responsive to LPS stimulation and produce nitric oxide (NO) as a marker of
activation. NO is a potent inflammation mediator molecule and also is responsible for
oxidative stress induced cell death.[13] Studies have shown that if the activated
macrophages were responsive to anti-inflammatory therapeutics, the amount of NO
production will decrease.[116] Therefore, the extent of NO reduction could be taken as a
measurement of anti-inflammatory potency of therapeutic materials. In the present study,
the anti-inflammatory effect of prodrug and its released products were determined by
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comparing the production of NO between the activated cells treated with these
compounds and untreated control. It has been shown that glucocorticoids can exert antiinflammatory effects within a wide range of dosage, from 0.001 nM to 0.1 mM or
higher[135]. In the present work, I selected a dosage in the middle of the range (i.e., 1.1
µM of prednisolone) to assay NO production.
The inhibitory effect of prodrug and its precursor polymer on NO production in
RAW264.7 macrophages were compared (Figure 17). A 40% reduction in NO production
was observed when the cells were treated with prodrug, suggesting that the prednisoloneconjugated prodrug has an anti-inflammatory effect against activated macrophages.
However, the anti-inflammatory effect of prodrug was less potent compared to activated
cells treated with the same amount of free drug, which showed over 60% reduction in NO
production.
It is unclear at present how the prodrug exerts its anti-inflammatory action. From
the release profile at pH 7.4 (Figure 14) I can rule out the possibility that a significant
portion of the conjugated drug was cleaved off the polymer carrier and interacted with the
activated cells after 24 h of incubation. Based on the mechanisms of the cellular actions
of glucocorticoids reported by Buttgereut et al. [135], I speculate that all the free drug
molecules can participate in both the genomic mechanisms and nongenomic mechanisms.
However, in the form of prodrug, it is likely that the nongenomic, receptor-mediated
mechanisms are dominant. Depending on the polymer chain conformations, it is possible
that only a portion of the conjugated drug molecules will be accessible to the receptors.
Therefore, the prodrug form is less effective to inhibit NO production than free drug.
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Figure 17. NO production by LPS activated macrophages, LPS activated macrophage
treated with either polymer PNVP-NH-NH2, prodrug PNVP-pred, or free drug
prednisolone, respectively. Non-activated macrophages treated with polymer PNVP-NHNH2 alone were also included. Cells without LPS activation served as control. Data
shown are average ± STD (n = 3).
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It will be informative to elucidate the mechanism underlying the therapeutic effect of the
prodrug in a future study. Along with the prodrug, I was also interested to examine
whether the polymer precursor (PNVP-NH-NH2) had any biological activity, since it will
be one of the major release products in addition to the conjugated drug. Of particular
relevance are whether the polymer has any anti-inflammatory effect, and more
importantly, whether the polymer is stimulatory towards macrophages.
As shown in Figure 17, when LPS activated macrophages were treated with the
polymer precursor (PNVP-NH-NH2) at a level equivalent to the prodrug, no significant
difference was observed in the amount of NO produced as compared to LPS activation
alone, suggesting that the polymer precursor had no anti-inflammatory effect.
Furthermore, when non-activated macrophages were exposed to the polymer precursor,
the level of NO production remained similar to that of the non-activated negative control.
It implies that the polymer will not induce any macrophage activation and thus would be
suitable as a drug carrier to treat host inflammatory response to implanted electrodes.
The other important aspect of the bioactivity study was to determine whether the
therapeutic nature of the drug was preserved after subjection to the conjugation reaction
via the hydrazone linkage. To address this question, prodrug solution was prepared with
either a PBS buffer (pH = 7.4, physiological condition) or an acetate buffer (pH = 5.0,
inflamed tissue) and incubated at 37 °C. At various time points, an aliquot of solution
was withdrawn and stored at -20 °C until the bioactivity study was performed. LPS
activated RAW264.7 macrophages were used and treated with the various prodrug
solutions mentioned above.
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Figure 18. NO production by LPS activated macrophages with and without treatment of
prodrug solutions subjected to release for up to 10 days at pH 5.0 and 7.4. Cells without
LPS activation served as control. Data shown are average ± STD (n = 3). * indicates p <
0.05.
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The therapeutic effect was gauged through level of inhibition of NO production. As
shown in Figure 18, when cells were treated with prodrug solutions obtained after 1-day
incubation, the level of inhibition on NO production was similar to the original day 0
samples, regardless of the buffer pH. However, when treating cells with samples
collected after 10-day incubation, a significant improvement (p < 0.05) in NO inhibition
was observed for the sample prepared in the acidic buffer, where the inhibition level
increased from 40% to 50%; but the sample of physiological pH did not show any
statistical change.
On one hand, these results confirmed that more drug release occurred under acidic
condition where hydrolysis of the hydrazone bond was accelerated, consistent with the
HPLC data. On the other hand, these results indicated that the released prednisolone
retained its therapeutic activity, suggesting that the conjugation scheme did not
compromise the bioactivity of the drug. Though the HPLC data showed drug release at
day 10 for the normal physiological pH, it is possible that the amount of free drug in the
solution was below its therapeutic concentration, and therefore not able to further reduce
NO production. Overall, these cell culture results proved that the synthesized prodrug
was sensitive to pH and able to release more potent free drug at lower pH. It could be
used as a smart drug delivery system to actively treat inflammation against implanted
neural electrodes, that is, a more severe inflammatory response will result in further
tissue acidosis which in turn triggers more drug release to counteract on the
inflammation.
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Besides its therapeutic effect, of equal importance to the neural electrode
application is the biocompatibility of the prodrug in the CNS. It is critical that the
prodrug and its released product, i.e. the polymer precursor PNVP-NH-NH2 do not
exhibit toxicity towards neurons, which are the sole target of the electrode. Therefore, I
studied toxicity both quantitatively and qualitatively. For quantitative analysis, the WST1 assay was adopted. It is a standard assay used widely for analysis of cytotoxicity. Its
working principle is based on the reduction of a tetrazolium salt by cellular mitochondrial
dehydrogenases to a water-soluble salt, which can be photometrically quantified at 450
nm. In this assay, the untreated neurons were used as a positive control and all values
from the experimental group were compared with this set of data. As shown in Figure
19a, the reduction of WST-1 was unaffected by prodrug or its polymer precursor, and no
significant difference was observed between the viability of treated neurons and the
control. For qualitative analysis, neuron morphology was observed via a live Calcein AM
staining. The confocal images (Figure 19b-d) illustrated that regardless of the treatment,
the cortical neurons were viable (good fluorescent intensity) and displayed morphology
and neurite extension comparable to the control. Both of the polymers used in the LBL
process, that is, PNVP and PAA, are non-biodegradable. One will be concerned about the
bioeliminability of these polymers in vivo. Although I used the well-studied high
molecular weight PAA in this proof-of-concept study for LBL construction, future
studies can use a degradable polymer such as poly(glutamic acid) to replace the nondegradable PAA. For PNVP, even though it is non-degradable, it can be eliminated if the
molecular weight is maintained below 100,000 g/mol.
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Figure 19. (a) In vitro neural cytotoxicity of prodrug PNVP
PNVP-pred
pred and precursor polymer
PNVP-NH-NH2. Data shown are average ± STD (n = 3). Confocal images show
morphology of neurons following 48 h treatment with either (b) prodrug PNVP-pred,
PNVP
(c)
precursor polymer PNVP-NH
NH-NH2, or (d) non-treated
treated control. Scale bar = 100 µm.
µ
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2.3.4 Prodrug diffusion in a simulated brain tissue model
Distribution of prodrug in the brain tissue around the implanted electrode is an
important parameter for clinical applications due to the importance of therapeutic
concentrations to combat inflammation. Therefore, a simple diffusion experiment in a
simulated brain tissue was designed to provide basic information of the therapeutic
concentration.
A silicon wafer was firstly coated with fluorescent prodrug analog. Then the
coated silicon was embedded into an agarose hydrogel, simulating the gel-like brain
tissue environment. After incubation of the system for a predetermined time, the
fluorescent prodrug analog diffused away from the electrode (Figure 20). The fluorescent
images were recorded using a fluorescent microscope. The concentration distribution of
the prodrug analog around the electrode was therefore calculated.
The raw images were shown in the appendix (Figure 50). The processed
fluorescent intensity along the diffusion pathway was shown in Figure 21.
The fluorescence intensity at 4200 µm was firstly subtracted as the background
value to obtain corrected fluorescent intensity. To simplify the calculation, the intensity
curve was divided into three regimes, with linear distribution in each regime (Figure 22).
The equation for the simplified intensity, I(x), was shown below:
82,
456) = 7−0.046 + 92,
−0.000836 + 35,

6 < 250
250 < 6 < 1800C
1800 < 6 < 4200

where x is the diffusion distance from the surface of the Si wafer.
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Figure 20.. Scheme of prodrug diffusion in the simulated brain model by a block of
agarose gel.
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Figure 21. Fluorescent intensity of prodrug analog as a function of distance away from
the Si wafer.
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Figure 22. Approximation of fluorescent intensity of prodrug analog as a function of
distance away from the Si wafer
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The prodrug concentration at distance x, c(x), was obtained based on the
assumption of its proportional correlation the fluorescent intensity, as shown in the
following equation.
D56 = E456

9

where σ is a constant.
In the cube of the diffused prodrug analog (Figure 23), it is reasonable to assume
the same concentration along the shank of electrode (z).
Therefore, the total amount of prodrug in the gel block (n0) could be calculated
according to the following equation:
4200

F0

D56 GH6 =

0

10

where A is the area of Si wafer. Furthermore, n0 can be expressed by the
following equation:
0

= ΓJGK

11

where Γ is the amount of polymer per layer from LBL assembly. A typical value
is 1 mg/m2/layer, from many previous reports and my own QCM results. Therefore, 1
mg/m2/layer is used for current calculation.
N is the layer number for the prodrug analog. 8-layer was taken for calculation.
Φ is the drug loading capacity of the prodrug. In the current study, Φ is taken as
160 mg/g, which is the drug loading capacity of PNVP-pred.
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Figure 23. Scheme of simplified cube of diffused prodrug away from the Si wafer.
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Finally, the concentration of prodrug could be determined at any location along
the substrate. Take the concentration at 100 µm away from the substrate for example, the
concentration was calculated as 2.36 µM. The brief calculation procedures are shown
below:
E=

=

G TF

V

F

-

456 GH6

=

F

-

ΓJGK
456 GH6

1LM
L × 8 NOPQ × 0.16 M × G
M
NOPQ

U

82H6 + F V

-

5−0.046 + 92 H6 + F U

5−0.0836 + 35 H6W

= 0.0000104 XM/L+
D5100 L = E45100 L = E × 82
= 0.00085 XM/L+
= 2.36 Z [QPHP \]^ ^ P
The ultimate goal of this experiment is to determine the spatio and temporal
distribution of therapeutic at any time period and any location. A more rigorous process
will be a combination of theoretical prediction and experimental validation. Experimental
results will provide parameters such as the diffusion constants for theoretical calculation
and proofs for the theoretical models. Theoretical models will in turn give comprehensive
understanding of the drug concentration distribution. The above model needs to be
improved in several ways such as the reproducibility, accurate description of the
fluorescent intensity curve, etc. Although the current model is very rudimental, it is a
simple and first step toward determination of kinetics of drug distribution in the brain
tissue.
63

2.4 Conclusions
A glucocorticoid-polymer prodrug was synthesized by conjugating prednisolone
to functionalized PNVP through a hydrazone bond. Drug release from the prodrug was
sensitive to pH as hydrolysis of the hydrazone linkage was enhanced under acidic pH.
Besides being a drug carrier, the prodrug was also compatible with the LBL technique
leading to hydrogen-bonded PAA/prodrug multilayers successfully deposited onto silicon
wafers and quartz plates through LBL assembly. The prodrug and its released products
demonstrated good biocompatibility with neurons, and the conjugated drug retained its
therapeutic effect by successfully inhibiting NO production from activated macrophages.
Collectively, these results suggest that the glucocorticoid-PNVP prodrug can serve as a
promising and versatile drug delivery system. It can be easily applied to neural electrodes
without compromising the electrical property of the implant, and can potentially realize
tissue response-regulated drug release based on tissue acidosis. Future studies include in
vitro anti-inflammatory study of prodrug on the brain macrophage microglia as well as
astrocytes, application of the prodrug on implantable neural electrodes and investigation
of the effectiveness of the prodrug in actively managing tissue response to electrodes in a
rat model.
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Chapter 3
Water Soluble Antioxidant Derivative Poly(Triethylene Glycol Methyl
Acrylate-co-α-Tocopheryl Acrylate) as a Potential Prodrug to Enable
Localized Neuroprotection
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An article presenting part of the results in this chapter has been submitted to Acta
Biomaterialia. [Cao Y, He W. Water soluble antioxidant derivative poly(triethylene
glycol methyl acrylate-co-α-tocopheryl acrylate) as a potential prodrug to enable
localized neuroprotection.] The first author (Yu Cao) finished all of the experiments in
this study. The corresponding author (Dr. Wei He) is the advisor of Yu Cao and
financially supported this work.

3.1 Introduction
Reactive oxygen species (ROS) are a class of oxygen free radicals and related
molecules that are capable of exerting oxidative stress on cells when produced in excess.
When the amounts of ROS are generated beyond the limit of natural antioxidant defense
systems like reductive glutathione (GSH) and antioxidant enzymes, cells start to lose
normal functions followed by necrosis[136, 137]. ROS generation has been used to
correlate inflammatory cell

response

to

biomaterials

in

numerous

in

vitro

biocompatibility studies. For example, nanoparticles were shown to trigger an oxidative
stress on cells by inducing the production of intracellular ROS, leading to subsequent
cellular toxicity cascade reactions [138, 139]. Another example of ROS implication in
biomedical material application is the oxidative stress response resulted from degradation
products of poly(lactic acid) (PLA) [140, 141]. Such a high relevance of oxidative stress
is also demonstrated by recent renewed interest in regulating oxidative stress to modulate
the tissue response to biomaterials and improve their biocompatibility.
For biomaterials used in neural tissues, such as MEAs, it is of utmost importance
to control oxidative stress. Very often, neuro-inflammation is accompanied by oxidative
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stress

[142,

143].

Furthermore,

the

insoluble

nature

of

MEAs

stimulates

microglia/macrophage cells into a “frustrated” phagocytosis mode. The process of
“frustrated” phagocytosis is known to produce excess degradative substances such as
hydrogen peroxide in an effort to destroy the implant [144, 145]. The consequence of
these molecular actions is cellular damage and death. Although there have been many
studies using localized release of anti-inflammatory agents to control inflammation
against MEAs, few reports have addressed direct protection of cells from oxidative stress.
Astrocytes are one type of glial cells in the brain supportive of neuron functions.
It has been shown that astrocytes can protect neurons from oxidant hydrogen peroxide
toxicity [38, 39]. Therefore, we suggest that it is rational to shield astrocytes from
oxidative stress associated with implantable MEAs. Such an approach could potentially
lead to improving survival of neurons that are vital for long-term MEAs functions.
To protect cells from oxidative stress, a common strategy is to use therapeutic
antioxidants. There are a variety of natural antioxidant molecules serving physiological
roles of scavenging ROS. These include α-tocopherol (vitamin E, Ve) , trans-ferulic acid
[146], ascorbic acid [147], α-lipoic acid [148], as well as proteins such as glutathione
peroxidase [149], and myo-inositol hexaphosphoric acid and its derivatives [150-152].
Among these molecules, the antioxidant potency of Ve lies in its capability to scavenge
free radicals that cause lipid peroxidation and damage of cell membrane. Ve has been
widely selected as a defense against oxidative damage in a biomaterial context. For
example, Ve has been used as an additive to stabilize PU elastomer in vivo [153]. New
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dialysis membranes coated with Ve have also been developed [154]. In this study, I
choose Ve to serve as the antioxidant agent to protect astrocytes from oxidative stress.
Successful localized delivery of Ve around MEAs for in vivo applications needs
to overcome several hurdles. First, Ve is highly hydrophobic, which is unfavorable for its
solublization and transportation in the predominantly aqueous environment presented by
the physiological tissues [155, 156]. Second, use of Ve may be limited by factors such as
unfavorable pharmacokinetics and a short action time due to fast metabolisation [157].
Last, the delivery strategy needs to be carefully designed to avoid any compromise of the
electrical properties of MEAs. To address the first two concerns, one can adopt a prodrug
approach, that is, converting antioxidants into polymeric antioxidants to improve the
transport and metabolic stability of antioxidant molecules. Furthermore, the rate of drug
degradation can be reduced, ensuring a longer presence than free antioxidants [158, 159].
Such prodrugs can be formed by linking antioxidant molecules to polymeric matrices
through covalent bonds [160, 161]. For example, polymer-tocopherol prodrugs were
synthesized to treat porcine sperm cell. The intracellular sperm levels of Ve were largely
increased. As a result, the endogenous fatty acid degradation under oxidative stress was
greatly reduced [161]. For the last concern of maintaining electrical properties of the
implant, I will design the prodrug to be compatible with LBL assembly process to
minimize any impedance burden to the MEAs.
In this chapter, a synthetic antioxidant polymer derivative of Ve was designed
with the goal to enable localized delivery of antioxidants to the neural tissue around the
MEAs implant, and to present a pharmacological depot to protect cells from the injurious
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oxidative stress. The applicability of using this antioxidant prodrug with MEAs was
demonstrated through LBL film assembly on silicon substrates. In vitro astrocyte cultures
were carried out to study the cytotoxicity and anti-oxidation potency of the prodrug. To
elucidate the protective mechanism against oxidative stress, a free radical scavenging
assay was also performed.

3.2 Experimental Section
3.2.1 Materials
Acryloyl chloride, α-tocopherol, triethylamine, azobisisobutyronitrile (AIBN),
polyethyleneimine (PEI, Mw = 2,000 g/mol), 2,2-diphenyl-1-picryl-hydrazyl (DPPH) and
tannic acid (TA) were obtained from Sigma-Aldrich, USA. Deuterated chloroform was
obtained from Cambridge Isotope Laboratories, Inc., USA. Poly(acrylic acid) (PAA, Mw
= 450,000 g/mol) was purchased from Polysciences, Inc., USA. Tetrahydrofuran (THF),
dichloromethane (DCM), hexane, ethyl acetate, and anisole were purchased from Fisher
Scientific, USA. All reagents were used as received unless otherwise noted. Monomer of
triethylene glycol methyl acrylate (TEGMA) was kindly provided by Dr. Bin Zhao in
Department of Chemistry, UTK.
3.2.2 General characterization
1

H NMR and

13

C NMR spectra were recorded on a Varian Mercury 300 NMR

spectrometer. Fourier transform infrared spectroscopy (FTIR) was carried out on a BioRAD FTS6000 FTIR spectrometer. Gel permeation chromatography (GPC) was
performed at room temperature using PL-GPC 50 plus (an integrated GPC/SEC system
from Polymer Laboratories, Inc., USA) with a refractive index detector. THF was used as
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the carrier solvent at a flow rate of 1.0 mL/min. Standard monodisperse polystyrenes
(Polymer Laboratories, USA) were used for calibration. A Q-1000 differential scanning
calorimeter (TA Instruments, USA) was used to characterize thermal behavior of the
copolymers. UV-vis spectra were measured using a UV-vis spectrophotometer (Biomate
5 from Thermospectronic, USA). Ellipsometric measurements were performed on dry
LBL films in air using an L0116S Stokes ellipsometer (Gaertner scientific corporation,
USA) with He/Ne laser (632 nm) illumination at a 70° angle of incidence. A refractive
index of 1.465 was assumed for the dry film.
3.2.3 Polymer synthesis
The monomer α-tocopherol acrylate (VeAc) was synthesized (Figure 24a) based
on prior literature [161]. Copolymerization of VeAc and TEGMA was conducted at
different feeding ratios, with molar percentage of VeAc as 5%, 10%, 25%, and 50%. In a
typical procedure, VeAc (0.362 g, 0.065 mol/L), TEGMA (3.107 g, 1.234 mol/L), AIBN
(0.037 g, 0.019 mol/L), and anisole (12 mL) were added into a 50 mL flask. The mixture
was then subjected to three freeze-thaw cycles to remove oxygen. Polymerization
reaction took place at 70 °C for 5 h. The polymer was then precipitated in hexane,
redissolved in anisole, and reprecipitated in hexane for purification. The obtained
polymer (PVT) was dried overnight in a vacuum oven at 70 °C (3.029 g, 87% yield).
3.2.4 LBL assembly
The self-assembled films were prepared on silicon substrates with a 100 nm thick
oxide layer (University Wafer, USA). Before layer deposition, the silicon wafers were cut
into small squares (1 x 1 cm).
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Figure 24.. (a) Synthesis of monomer α-tocopheryl acrylate
crylate (VeAc). (b) 1H NMR
characterization of VeAc in CDCl3. Successful acrylation of Ve is confirmed by the
observation of peaks at chemical shifts of 6.62, 6.36 and 5.98 ppm, corresponding to the
vinyl protons. (c)

13

C NMR characterization of VeAc in CD
CDCl3. Characteristic peaks

associated with the acrylate carbons are identified.
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All substrates were cleaned in a boiling piranha solution (3:1 concentrated H2SO4 : 30%
H2O2 v:v; piranha solution reacts violently with organics and should be handled with
extreme caution) for 30 min, washed with copious amount of water, and dried under
nitrogen. The substrates were first immersed in a PEI solution (1.5 mg/mL) for 30 min,
followed by rinsing in water for 1 min. The PAA/PVT (or TA/PVT) multilayers were
then assembled by alternating immersion of the substrates in solutions of PAA (or TA)
and PVT for 5 min, respectively.
Between each step, the excess material was removed by rinsing the substrates
with HCl solution (pH = 3.0) for 1 min. Solutions of PAA, TA, and PVT were prepared
to a concentration of 0.5 mg/mL (pH = 3.0) using ultrapure water (Milli Q-plus system,
Millipore, USA) with a resistivity of 18.2 MΩ·cm. The assembly process was monitored
with ellipsometry. To evaluate stability of the multilayers under physiological conditions,
silicon substrates coated with PAA/PVT or TA/PVT multilayers were immersed in
phosphate buffered saline (PBS, pH = 7.4) for 10 min, and subsequent ellipsometric
measurements were carried out to characterize the thickness of remaining films.
3.2.5 Quartz crystal microgravimetry (QCM)
QCM measurements were conducted at room temperature using a Q-sense device
(E4) with a flow cell (Q-Sense AB, Västra Frölunda, Sweden). A gold-coated 5 MHz
AT-cut crystal was excited at multiple overtones, and the change in the resonance
frequency was recorded. After deposition of the initial layer of PEI (1.5 mg/mL), the
chamber was washed with water, after which the solution of PAA or TA was introduced
into the chamber and allowed to adsorb for 5 min. Subsequently, the chamber was
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washed again with HCl (pH = 3.0) and then filled with PVT solution, allowing an
adsorption time of 5 min. The multilayer film was then assembled by alternating
incubations between PAA (or TA) and PVT.
3.2.6 In vitro cytotoxicity assay
In vitro cytotoxicity of the PVT prodrug was examined using the A172 human
astrocyte cell line (ATCC, USA). Cells were cultured in Dulbecco’s modified Eagle’s
medium

(DMEM)

supplemented

with

10%

fetal

bovine

serum

and

1%

penicillin/streptomycin. Cells were maintained at 37 °C in 5% CO2 with 95% relative
humidity. Prior to cytotoxicity test, cells were harvested using a trypsin–ethylenediamine
tetraacetic acid (EDTA) solution (0.25% trypsin–0.038% EDTA) and diluted to a density
of 5 × 105 cells/mL. The cell suspension was added into 96-well plates at 100 µL/well,
and cells were allowed to attach overnight. Cell culture medium was then aspirated the
next day and replaced with fresh medium supplemented with PVT at different
concentrations (either 10 or 500 µM). Cells were incubated overnight and polymer
cytotoxicity was determined using an MTT assay (Promega, CellTiter 96, USA)
according to the manufacturer’s instruction. Positive (without any treatment) and blank
(without cells) controls were also included. Cell viability was examined by comparing the
absorbance of treated cells to that of the positive control. Statistical analysis was
conducted using Student’s t-test. Cell morphology was also recorded using an inverted
optical microscope (ZEISS Observer A1, USA).
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3.2.7 In vitro cell protection against oxidative stress
A172 astrocytes were harvested using trypsin–EDTA solution and diluted to a
density of 3.3 × 104 cells/mL. The cell suspension was added into 96-well plates at 100
µL/well, and cells were allowed to attach overnight. The cultures were then incubated
with Ve or PVT at a concentration equivalent to 500 µM Ve for 1 h before exposure to
hydrogen peroxide (500 µM) to induce toxic oxidative stress. After 16 h, cell viability
and morphology were examined using the MTT assay and optical imaging, respectively.
The protective effect was inferred from the percentage of cells survived by normalizing
the absorbance of treated cells to that of control cells without hydrogen peroxide
treatment.
3.2.8 Free radical scavenging assay
Ve was released from PVT by dissolving the prodrug in a saturated KOH solution
with saponification at 70 °C for 30 min. Released Ve was extracted by hexane twice,
followed by solvent evaporation. The amount of Ve recovered was quantified using an
Agilent 1100 HPLC system with a variable wavelength UV detector. A reverse phase
C18 column (Phenomenex, 4.6 × 100 mm, 2.5 µm) was used for the analysis with
acetonitrile and methanol (95:5, v/v) as the mobile phase. The flow rate was set constant
at 1.5 mL/min. A sample injection volume of 20 µL was used for all evaluations.
Detection of Ve was made by UV absorption at 280 nm. The antioxidation property of
the released Ve was examined using a DPPH free radical scavenging assay following
procedures modified from a previous report.[162] Briefly, aqueous solution (1 mL) of
various samples was added to 3 mL of freshly prepared DPPH solution (0.025 mg/mL in
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methanol). The tested samples included PVT, released Ve from PVT, and commercial
grade Ve, and the concentrations were kept the same to be equivalent to 350 µM Ve.
Absorbance at 550 nm was measured on a UV-vis spectrophotometer. The percentage of
remaining DPPH free radicals in each experimental sample was calculated by
normalizing the corresponding absorbance to that of the control without any sample
addition.
3.2.9 Impedance measurement
The effect of the multilayers of (PVT/PAA) on the electrical properties of Si
MEAs was evaluated by impedance spectroscopy. A micromachined single shank acute
probe (16 recording sites, model: A1×16-5mm-100-177-A16) obtained from NeuroNexus
Technologies, Inc. was coated with (PVT/PAA) multilayers, and the impedance of the
probe sites was measured before the coating, after 8 bilayers, and 16 bilayers,
respectively. Electrochemical impedance spectroscopy was done using Precision
impedance analyzer 4294A (Agilent). A solution of 0.1 M PBS buffer was used as the
electrolyte. AC sinusoid signal of 5 mV amplitude, with the DC potential set to 0V was
used as the input. The value of the impedance was determined around the biologically
relevant frequency of 1 kHz.

3.3 Results and Discussion
Oxidative stress can impose a significant challenge on cell survival if not
controlled properly. Such an issue is of particular relevance to delicate brain tissue as it is
highly prone to oxidation damage. In order to ensure the proper function of devices
implanted in brain such as recording MEAs, it is reasonable to suggest that a potential
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strategy is to maintain a healthy state of brain tissue at the interface through localized
delivery of antioxidants. Toward this goal, I proposed to use an antioxidant prodrug. The
prodrug was designed to serve two key functions: carrier of antioxidants and readily
applicable for MEAs through LBL assembly. These features were achieved through
simple copolymerization of α-tocopheryl acrylate (VeAc) with triethylene glycol methyl
acrylate (TEGMA) to make poly(triethylene glycol methyl acrylate-co-α-tocopheryl
acrylate) (PVT) prodrugs. VeAc is a derivative of the potent natural antioxidant vitamin
E (Ve). The phenolic hydroxyl group allows straightforward functionalization of Ve into
a polymerizable VeAc monomer. TEGMA is selected as the co-monomer to both
increase water solubility of the prodrug and endow LBL compatibility through its
hydrogen bond accepting ethylene glycol units.
3.3.1 Synthesis and characterization of the antioxidant prodrug
The antioxidant prodrug PVT was prepared through a conventional free radical
copolymerization of monomers TEGMA and VeAc (Figure 25) with AIBN as the
initiator. Prior to polymerization, the synthesized monomer VeAc was verified through
1

H NMR and

13

C NMR, and the results agreed well with the expected structure (Figure

24b and c). A series of PVT prodrugs were prepared by varying the feed molar ratio of
the two monomers. The number average molecular weights Mn of the copolymers were in
the range of 14,000-25,000 g/mol with a relatively high polydispersity (), which is typical
for acrylate polymers synthesized by free radical polymerizations in solution.
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anti-oxidant vitamin E based prodrug PVT.
Figure 25. Synthesis of anti
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Table 1. Molecular weight and compositional data of PVT prodrugs.

Prodrug

VeAc (mol%)
actual
feeding

Mn
(g/mol)

PDI

PVT4

3.7

5

21,700

3.29

PVT8

7.8

10

24,900

1.87

PVT24

23.7

25

21,700

1.50

PVT45

45.5

50

14,500

1.43
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The chemical structure of the PVT prodrug was characterized with 1H NMR. As
shown in Figure 26, a series of signals at chemical shift 3.35-3.75 ppm and around 4.20
ppm corresponded to the alkoxy protons of the ethylene glycol units in the side chain of
the TEGMA moiety. The peaks around 0.89 ppm originated from the methyl protons in
the alkyl tail of the VeAc component.Based on the characteristic peak from TEGMA
(4.20 ppm) and VeAc (0.89 ppm), chemical compositions of PVTs were calculated. The
molar percentage of VeAc incorporated into the final copolymers was 3.7%, 7.8%,
23.7%, and 45.5%, respectively.
The use of copolymerization allows the preparation of a series of PVT prodrugs
with different therapeutic capacities by controlling the copolymer composition. Since
both monomers are in the acrylate family, similar reactivity is expected between the two
monomers, and the actual composition of the obtained copolymer should be consistent
with that in the initial feeding. Such an expectation is confirmed from the 1H NMR
results, where the initial molar feeding ratio of VeAc ranging from 5% to 50% resulted in
a final molar percentage of VeAc incorporated at 3.7% to 45.5%, respectively. Attempts
have also been made to synthesize a homopolymer of VeAc. However, no polymerization
occurred, which could be attributed to the antioxidant properties of the α-tocopheryl
group. Although the exact cause is beyond the scope of this paper, a similar result has
been reported showing low efficiency of making methacrylate copolymers with high
molar percentage of Ve derived methacrylate [163]
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Figure 26. 1H NMR characterization of prodrugs (a) PVT4, (b) PVT8, (c) PVT24, and (d)
PVT45 in deuterated chloroform. Characteristic peaks from each monomer were labeled.
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The chemical compositions of PVTs were further confirmed using UV-vis
spectroscopy. As shown in Figure 27, λmax of the Ve spectrum appeared at 292 nm, while
that of PVT copolymers shifted to 285 nm. Such a blue shift in the peak absorbance can
be attributed to the substitution of the phenolic –OH group in Ve with an ester group in
the PVT polymer. No significant absorbance was observed between 260-320 nm for the
polymer analog of the prodrug (i.e. PTEGMA). Using a predetermined standard curve of
Ve absorbance, the molar composition of VeAc in PVT4 and PVT8 were calculated to be
4.3% and 9.0%, respectively. These results were comparable to those obtained from the
1

H NMR spectra.
Chemical structures of the monomer VeAc and PVT copolymer were also

characterized by FTIR (Figure 28). The characteristic phenolic –OH group from Ve is
absent in both VeAc and PVT since no peak was observed around 3509 cm-1, which
corresponds to the –OH stretching. The strong absorbance around 1734 cm-1 in VeAc and
around 1743 cm-1 in PVT corresponded to the stretch vibration of ester C = O group.
Furthermore, absorbance peaks around 1637 cm-1 and 1580 cm-1 in VeAc were due to C
= C stretching vibration from both the vinyl group and the phenyl group.
Thermal behavior of the PVT copolymers was characterized using DSC (Figure
29). All PVTs displayed a glass transition temperature (Tg) well below body temperature,
ranging from -55 °C to -30 °C when the fraction of VeAc increased from 4 mol% to 45
mol%.
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Figure 27. UV spectra of (a) PTEGMA (10 mg/mL), (b) Ve (0.05 mg/mL), (c) PVT4 (1
mg/mL), and (d) PVT8 (1 mg/mL) in ethanol solution.
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Figure 28. FTIR characterization of (a) Ve, (b) monomer VeAc, and (c) prodrug PVT4.
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Figure 29. DSC thermograms of prodrugs PVT4, PVT8, PVT24, and PVT45. Glass
transition temperature, Tg, for each of the prodrug is -55, -52, -40, and -30 °C,
respectively.
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Such a correlation is expected as a higher amount of the bulky and rigid Ve pendant
group will hinder the ability of the polymer chains to undergo segmental motion, thus a
higher Tg. No melting peak was observed when the samples were heated to a temperature
as high as 200 °C (Figure 30).
Varying compositions of PVTs also provided us an opportunity to identify the
highest antioxidant loading capacity while maintaining reasonable water solubility. As
mentioned earlier, the highly hydrophobic characteristic of Ve hinders its transportation
through the predominantly aqueous extracellular medium of the physiological tissues. In
contrast to the nearly insoluble nature of Ve in water (0.021 mg/mL or 49 µM) [164], the
PVT prodrugs can be formulated to achieve significantly higher solubility. In particular,
PVT4 is the most water soluble, at a feasible concentration of 3.1 mg/mL that
corresponds to 500 µM of Ve. PVT8 and PVT24 possessed medium solubility (0.5
mg/mL), while PVT45 exhibited the lowest water solubility (0.02 mg/mL). The trend of
water solubility correlates well with our expectation that the more of the hydrophobic
VeAc monomer is incorporated into the prodrug, the less water soluble it will become.
Water solubility of the prodrug is also highly relevant for its practical deployment
to the tissue-implant interface using the LBL method, since the most commonly used
solvent for LBL is water. Typically, I have been using a minimum concentration of 0.5
mg/mL for our LBL assembly processes [34]. Therefore, prodrug PVT45, which has the
highest molar percentage of VeAc, is not applicable for use in LBL.
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Figure 30. Full DSC thermograms of prodrugs PVT4 and PVT45.
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3.3.2 Application of PVT for LBL assembly
LBL is a simple and convenient technique for surface modification of biomedical
implants. Hydrogen-bond mediated LBL has been proposed to obtain well-engineered
multilayer structures on neural MEAs to resolve the traditional dilemma between drug
loading and preservation of electrical property of electrodes [34]. In the current work, I
took advantage of the tunable stability of hydrogen bonding and rationally designed LBL
parameters to achieve the bonus feature of forming a drug depot around the implant. As
proposed schematically in Figure 31, prodrug-embedded detachable multilayers can be
prepared on the electrode by incorporating an underlying sacrificial multilayer that is
dissociable at physiological pH. Such a design could help confine the polymer
therapeutics within the vicinity of the implant-tissue interface and exert therapeutic
actions locally.
To realize the design, two types of hydrogen-donating molecules were needed to
form hydrogen-bonding with our hydrogen-accepting prodrug PVT. Among the many
well–studied hydrogen-donating molecules, I selected poly(acrylic acid) (PAA) that is
rich in carboxyl groups, and tannic acid (TA) that is rich in phenolic hydroxyl groups [55,
165] (Figure 32a and b). Intermolecular hydrogen bonds are available between the
hydrogen-accepting ether oxygen in the pendant ethylene glycol groups in PVT and the
hydrogen-donating carboxyl groups in PAA or phenolic hydroxyl groups in TA. PAA is
chosen for physiologically disruptable layers because of its low pKa (4.3), while TA is
employed to maintain layer stability due to its high pKa value (8.5). The additional
benefit of using TA is to capitalize on its biological properties such as antibacterial and
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antioxidant activities [166]. The PAA/PVT and TA/PVT multilayers were constructed on
silicon wafers with PEI as a precursor layer. Silicon is selected as the substrate because of
its prevalent use for implantable neural MEAs [47, 48].
Ellipsometric measurements showed the layer thickness increased linearly with
the layer number, allowing easy control of drug loading capacity (Figure 32c). Eight
bilayers of PAA/PVT and TA/PVT were 277 nm and 114 nm thick, respectively. For the
same number of layers, a thicker film was obtained using PAA/PVT compared to that
with TA/PVT. Such a difference could be due to molecular size disparity, as PAA has a
much higher molecular weight (450,000 g/mol) than TA (1701.2 g/mol). To demonstrate
the tunable stability of multilayers prepared with the same PVT prodrug, a simple
immersion test was done in PBS, simulating the physiological condition of human tissue.
The stability was characterized by the change of film thickness before and after
immersion for 10 min. As shown in Figure 32d, a drastic decrease in film thickness, from
277 nm to 4 nm, was observed for PAA/PVT multilayers. The remaining 4 nm film can
be attributed to the precursor PEI layer along with the adsorbed first PAA layer. It
indicates a significant film loss (more than 98% in thickness), which is attributed to the
low pKa of PAA (4.3). At physiological pH of 7.4, the carboxyl groups of PAA became
deprotonated, resulting in disruption of hydrogen bonding between PAA and PVT, which
in turn led to film dissociation. In contrast, the TA/PVT multilayers remained stable as no
significant change was noted in the film thickness after exposure to PBS (d).
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Figure 31. Schematic illustration of proposed use of prodrugs for surface modification of
implantable neural MEAs with LBL assembly to enable localized delivery of
antioxidants. The antioxidant prodrug PVT can be incorporated in two designs,
dissociable layers constructed with poly(acrylic acid) (PAA), and stable layers made with
tannic acid (TA) to serve as drug depots.
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Figure 32.. Schemes of LBL multilayer assembly pa
pair
ir and film characterization.
Hydrogen bonds formed between prodrug PVT and (a) PAA or (b) TA drives multilayer
growth. (c) Film growth was monitored by ellipsometric measurement of film thickness
as a function of number of PAA/PVT or TA/PVT bilayers. (d) Stability of the prodrug
containing multilayer films in physiological pH 7.4 phosphate buffer was examined by
comparing the film thickness before and after incubation.
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The high pKa (8.5) of TA provided stability for the TA/PVT multilayers due to the lack
of ionization of phenolic groups at physiological pH, therefore, preserving strong
hydrogen bonding between TA and PVT.
I also monitored film buildup as a function of the bilayer number in situ by
following the frequency change (∆f) with a QCM. As a complementary method to the
ellipsometry technique that characterized the dry multilayer films, QCM allowed studies
of in situ film growth in a hydrated state. As shown in Figure 32 and Figure 33a, a
comparison of the results showed that for eight bilayers of PAA/PVT, the ellipsometric
thickness was 277 nm and the QCM thickness was 414 nm. For TA/PVT multilayers, the
values were 114 and 342 nm, respectively, indicating an even higher degree of swelling
for this layer configuration. Considering that the TA/PVT multilayers are designed to
serve as the antioxidant reservoir situated at the periphery of the interface, its ability to be
well hydrated is highly desirable to minimize any irritation of the surrounding soft brain
tissue.
Another advantage of the QCM technique is that it allows the determination of
adsorbed mass by converting the frequency change using the Sauerbery equation [167]:
mQCM = C

∆ _
`

12

The mass deposited on the crystal, mQCM, is proportional to the normalized
frequency shifts, ∆fi/i, where i is the overtone number. For crystal sensors with a
resonance frequency of 5 MHz, the mass sensitivity constant C is 17.5 ng Hz cm-2, and
the frequency shift for the third overtone (i.e. i = 3) was used to determine mQCM.
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Figure 33. In situ characterization of multilayer growth on gold crystals using QCM. (a)
QCM frequency shifts and calculated film thickness during alternating deposition of PAA
and PVT or TA and PVT, and after incubation in PBS to demonstrate film stability. (b),
(c) Evolution of adsorbed Sauerbrey mass (Γ) plotted against layer numbers for PAA (or
TA), PVT, and total mass deposited.
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The mass information is essential for in vivo applications, as it forms the rationale
for finding the number of layers for a therapeutic concentration of the prodrug following
MEAs implantation. The calculated Sauerbrey mass for PAA/PVT and TA/PVT
following each layer deposition is shown in Figure 33b and c. For both multilayer
configurations, the mass increase per PVT layer appeared to be constant shown by the
linear increase in the Sauerbrey mass; whereas for the complementary PAA or TA layer,
the mass increase was close to exponential with an initial “slow-growing” regime. For
eight bilayers of deposition, the total mass adsorbed for PAA/PVT and TA/PVT was 73
and 60 µg/cm2, respectively. The mass contribution from PVT layer deposition was
higher than that from either PAA or TA layer, accounting for ~60% of the total mass.
Furthermore, the difference in multilayer stability in PBS was confirmed with QCM. A
significant recovery in the resonance frequency was quickly observed for the PAA/PVT
combination (within one minute of PBS incubation), indicating the rapid loss of
deposited multilayers (Figure 33a), whereas no change was noted for the TA/PVT
multilayer coated crystal.
In order to shed some light on the molecular behavior of the LBL assembly,
radius of gyration (Rg) and critical overlap concentration (c*) of polymers are calculated,
according to equations 6-7 shown in section 1.5. Take PAA/PVT system for example, the
results are tabulated in .
Rg values of PAA and PVT are 21 nm and 3 nm respectively. c* values of PAA
and PVT are 20 and 336 mg/mL respectively. The polymer concentration for LBL
assembly is 0.5 mg/mL, much smaller than c*.
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Table 2. Molecular parameters of PAA and PVT.

PAA
PVT
a

C∞

l (nm)

n

9a
11b

0.154a
0.154c

12500
200

M
(g/mol)
450000
21700

c*
(mg/ml)
21.08732 19.04073
2.948875 335.7574
Rg (nm)

Data are cited from handbook[168];b Data are from a similar polymer, poly (ethyl

acrylate) in handbook[168]; c The chain length is assumed to be that of acrylic acid.
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Therefore, adsorption of polymer is from non-overlapping chains in solutions.
According to the QCM results, the average layer thickness is 26 nm. Referred to a
previous report,[46] the molecular behaviors of the layer adsorption are proposed in
Figure 34. The individual polymer chain is adsorbed onto a surface due to the hydrogenbonding interaction. Polymer chains are then extended and reorganized to form tails and
loops extending from the surface.
It should be noted that in the above calculation process, several assumptions are
made for simplicity. Even though many estimations and limitations exist in the
calculation, it can provide a semi-quantitative insight on the molecular level of the LBL
process.
3.3.3 Cytotoxicity study of PVT
Besides satisfying the requirement of LBL compatibility, successful use of the
antioxidant PVT prodrug for MEAs implantation also calls for high biocompatibility.
Therefore, cytotoxicity of the prodrug on astrocytes was examined both quantitatively
and qualitatively. A commercially available A172 human astrocyte cell line was chosen
for this purpose. Since the Ve residue is linked to the acrylic backbone through a labile
ester bond, the prodrug could be hydrolyzed in the physiological environment and give
off Ve and the corresponding acrylic polymer. For this reason, cytotoxicity of these
potential released products, i.e. Ve and the polymer (approximated with a homopolymer
PTEGMA), was also tested. Because PVT4 has the highest water solublility among the
prepared PVT prodrugs, it was selected for all the in vitro biological studies.

95

Figure 34.. Proposed molecular behavior of polymer chains during LBL process mediated
by hydrogen bonding.
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Two concentrations equivalent to Ve were used for cell treatment, 10 µM and 500 µM. In
order to ensure dissolution of Ve at high concentrations, dimethylsulfoxide (DMSO) was
introduced as a co-solvent. The highest concentration used for cell culture was equivalent
to 500 µM of Ve, a value consistent with subsequent antioxidation study.
As shown in Figure 35, cells exposed to the PVT prodrug were as healthy as cells
in the control culture regardless of the prodrug concentrations. In comparison, for both
Ve and PTEGMA, cells showed good viability upon low dose treatment, while a
slightdecrease in viability (i.e. ~ 80% of the control) was observed for the high dose
condition. For the polymer PTEGMA, the slight toxicity could be attributed to residual
organic solvents in the polymer. Such an effect was also reflected from the difference in
cell morphology as shown by the qualitative phase contrast images (Figure 36). Unlike
the polarized spread shape presented by cells in the control culture, a more rounded
morphology was observed from cells exposed to the high concentration of PTEGMA.
3.3.4 Antioxidation study of PVT
Antioxidation property of PVT was investigated using A172 cells due to the
protective roles of astrocytes to neurons [38, 39, 169]. Hydrogen peroxide was chosen as
the oxidant stimulant because of its physiological relevance [170, 171]. Cell viability was
used as a caliber to examine whether the PVT prodrug can protect cells from oxidative
stress. Proper test conditions, including cell density, cytotoxic concentration of H2O2 and
protective concentration of Ve toward A172 cells, as well as exposure time were first
identified from pilot experiments.
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Figure 35. In vitro cytotoxicity of Ve, antioxidant prodrug PVT, and precursor polymer
analog PTEGMA on A172 astrocytes at concentrations of 10 and 500 µM (equivalent to
Ve). Data shown are average ± STD (n = 3). * p < 0.05. Statistical significance is
compared with the non-treated control.

98

Figure 36.. Representative phase contrast photomicrographs of cultured A172 astrocytes
subjected to various treatments for cytotoxicity study. Non
Non-treated
treated control culture is
shown for comparison. Scale bar = 100 µm
µm.
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A172 cells were challenged with hydrogen peroxide at at 500 µM that is sufficient
to induce significant oxidative stress and cause cell death. As shown in Figure 37a, cells
treated with hydrogen peroxide alone showed a very low survival rate, less than 10%.
When antioxidant Ve was added to the culture, it effectively protected cells from toxic
hydrogen peroxide, as the survival rate was improved to 68%. When cells were treated
with PVT prodrug at a concentration equivalent to 500 µM Ve, a viability of 43% was
obtained, which is indicative of protection. The protective effect is also supported by
qualitative morphological observations. In contrast to the characteristic polarized shape
with processes shown by healthy astrocytes (Figure 37c), marked morphological change
was observed for cells experiencing severe oxidative stress, resembled by strong
shrinkage of cell bodies and degeneration of processes (Figure 37d). With Ve or PVT
treatment, an intermediate state was observed, where both polarized and degenerated
cells were present (e and 7f). A higher percentage of polarized cells were seen in Ve
treated culture (Figure 37e) than PVT treated cells (Figure 37f), suggesting a lower
degree of cell protection by PVT.
It is summarized from above results that treatment with antioxidant Ve at 500 µM
showed substantial cytoprotection. While PVT with an equivalent Ve concentration was
also able to reduce cell death from H2O2 induced oxidative stress, the extent of protection
is lower than Ve supplemented to the culture in its free form. The protective mechanism
of Ve has been largely attributed to its capacity to scavenge free radicals that cause lipid
peroxidation and damage of cell membrane. Specifically, it can donate the phenolic
hydrogen to free radicals.

100

Figure 37. (a) In vitro protection of A172 astrocytes against injurious oxidative stress
induced by hydrogen peroxide (H2O2). Data shown are average ± STD (n=3). * p < 0.05.
(b) Antioxidation activity determined by the DPPH free radical scavenging method. (c)(f) Representative phase contrast photomicrographs of cultured A172 astrocytes
subjected to various treatments. Scale bar = 100 µm.
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Considering the essential role of the phenolic group for antioxidation, I hypothesized that
the cytoprotective effect shown by the PVT prodrug was a result of hydrolysis of the
labile ester bond between Ve and polymer chain, leading to the release of Ve in its active
form.
To test this hypothesis, antioxidant property was further studied using a free
radical scavenging method to elucidate the protection mechanism of PVT. DPPH is a
stable free radical useful for the investigation of antioxidation activity of compounds.
DPPH radical shows a characteristic absorbance peak around 550 nm. When interacting
with antioxidants such as Ve, DPPH radical can be reduced through abstraction of
transfer labile phenolic hydrogen atoms and the corresponding absorbance at 550 nm
decreases. The extent of radical scavenging, which correlates with antioxidant potency,
can be measured by the amount of decrease in absorbance.
As a positive control, fresh Ve was added to DPPH solution at a concentration of
350 µM and 90% of radicals were consumed (Figure 37b). When the prodrug PVT was
added at a concentration equivalent to 350 µM Ve, no free radical scavenging effect was
observed with almost 100% radical remaining at the end of reaction. PVT was unable to
interact with DPPH free radicals due to the lack of phenolic hydrogen. In contrast, when
DPPH was treated with Ve released from the PVT prodrug by disruption of the ester
bond, the effect was comparable to that with fresh Ve. This result suggests that the
released Ve retained its antioxidant potency and that the PVT protection of cells from
oxidative stress was derived from the breakage of the ester bond and release of Ve in an
active form. Such a mechanism correlates well with those reported on antioxidation
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activity of esterified derivatives of phenolic antioxidants [172]. The lower degree of
cytoprotection by PVT can be a result of slower release of Ve from PVT. It is well known
that hydrolysis of ester group is closely dependent on water accessibility around the
chemical bond [173, 174]. The strong hydrophobicity and steric hindrance of the Ve
segment can limit water diffusion and slow down degradation.
3.3.5 Electrical property of the modified electrode
Neural electrodes were coated with (PVT/PAA) layers using the LBL technique,
and the electrode impedance was measured before and after coating. This experiment was
designed to examine the influence of coatings on the conductivity of the electrode. The
thickness of coatings is expected to be the important parameter. Thin layers will not
change the impedance, while thick coatings could increase the impedance significantly.
In the latter case, the coated electrode will be immersed into PBS and the dissociable
property of (PVT/PAA) coatings will be proved from the impedance data of the recording
sites. It is expected that after incubation of the coated electrode in PBS, the coatings will
dissociate and the conductive recording sites will be exposed, returning the impedance to
original values.
The images of the electrode before and after coatings are shown in Figure 38. The
electrode was wrapped with some fluffy films around the tip, which could possibly be the
polymer complex. After 16 bilayers of deposition, the impedance is still low, comparable
to the uncoated electrode (Figure 39). The results demonstrate that current coated layers
did not change the electrical property of the electrode.
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(a)

(b)

Figure 38. Photomicrographs of a Michigan electrode before (a) and after (b) deposition
of 8 bilayers of (PVT/PAA)
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Figure 39. Impedance of recording sites after 8-bilayers (LBL (8)) and 16-bilayers (LBL
(16)) of LBL coatings. The value of the bare sites before coating was also shown for
comparison.
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3.4 Conclusion
Compositionally controllable antioxidant polymeric therapeutics based on Ve
were prepared. A significant improvement in the water solubility of Ve was observed.
The synthetic PVT prodrug can be used to modify substrates of neural MEAs implants
through hydrogen-bond mediated LBL technique. Multilayers with tunable stability at
physiological condition could be achieved simply by engineering the layer composition.
In vitro biocompatibility study showed that the PVT prodrug was non-cytotoxic toward
A172 human astrocytes. Furthermore, the prodrug was able to reduce astrocyte death
from hydrogen peroxide induced oxidative stress through the release of Ve in its active
form. Future studies include evaluation of protection of cortical neurons from oxidative
stress with the PVT prodrug and its effectiveness in improving the long-term function of
implantable neural MEAs in vivo. I believe that the strategy of using antioxidant prodrug
for direct cell protection from oxidative stress induced cell death provides a new
opportunity to improve the pharmacological control of brain tissue response to MEAs. In
addition to neural implant applications, our prodrug could also be applied to other
medical implants where reducing oxidative stress is essential.
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Chapter 4
Functionalized Biocompatible Poly(N-vinyl-2-caprolactam) with pHdependent Lower Critical Solution Temperature (LCST) Behaviors
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An article presenting part of the results in this chapter has been published on
Macromolecular Chemistry and Physics. [Cao Y, He W. Functionalized biocompatible
poly (N-vinyl-2carprolactam) with pH-dependent lower critical solution temperature
(LCST) behaviors. Macromolecular Chemistry and Physics, 2011, 212.] The first author
(Yu Cao) finished all of the experiments in this study. The corresponding author (Dr. Wei
He) is advisor of Yu Cao and financially supported this work.

4.1 Introduction
PVCL is water soluble and biocompatible, with LCST in the vicinity of
physiological temperature.[78] In conjunction with temperature, other stimuli including
pH have been used in developing dual responsive polymers. These dual responsive
polymers have been explored in applications including control of micelle structures,[89,
91, 93] advanced drug delivery systems,[85, 88, 98] fabrication of dual functional
nanofluidic devices,[86] and modification of gold nanoparticles.[90]
In order to introduce dual responsiveness to temperature and pH into PVCL based
materials, a similar copolymerization approach is commonly used, where VCL monomers
are copolymerized with other vinyl monomers such as MAA or acrylic acid (AA). For
example, aqueous solutions of linear copolymer of VCL and MAA with variable
compositions were prepared and the copolymers exhibited compositionally dependent
coil swelling behavior as a function of both pH and temperature.[175] However, similar
to its counterpart in the N-vinylamide family, such as N-vinyl-2-pyrrolidone (NVP), VCL
exhibits significantly lower reactivity comparing to methacrylates and acrylates due to
the inherently low reactivity of N-vinylamide.[82] Such drastic disparity in reactivity
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ratio makes compositional control a major concern in copolymerization-based
functionalization of VCL polymers. In order to minimize compositional heterogeneity in
the copolymers, special techniques such as gradual feeding strategy has been
proposed.[176] Alternatively, one could consider copolymerization of structurally similar
monomers of VCL that bear functional groups to obtain homogeneous copolymers. For
example,

Aoyagi

and

coworkers

designed

a

reactive

monomer,

2-

carboxyisopropylacrylamide (CIPAAm), a derivative from N-isopropylacrylamide
(NIPAAm).[177] They showed that copolymerization of CIPAAm with NIPAAm
resulted in homogeneous copolymer compositions and improved the phase transition
sensitivity.
In this chapter, the same principle was applied by copolymerizing VCL with its
functional derivative 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam (TBVCL), and
improved compositional control was achieved. The protected carboxyl groups in the
TBVCL units were converted to free carboxylic acids in the copolymer. Besides
maintaining the intrinsic thermo-sensitivity, the incorporated carboxyl groups enabled
pH-modulated LCST behavior. Sharp and reversible response was observed across a
broad range of pH values. The carboxyl groups can also provide an easy access for
further conjugation of bioactive moieties such as drugs, peptides, and proteins. Using
NIH/3T3 fibroblasts, I demonstrated that this PVCL copolymer was non-cytotoxic at low
concentrations. This simple PVCL copolymer with multi-characteristics, including
thermal and pH sensitivity, and reactivity for conjugation, will further expand the
biomedical applications of PVCL and provide a new option to the growing list of dual109

responsive biocompatible materials. Specifically, they could be added in the design
toolbox for achieving better control of tissue response to neural electrode. One possible
application could be correlating the pH-sensitivity of the PVCL polymers with the tissue
acidosis phenomenon following the implantation of the electrode. PVCL polymer chains
will be aggregated or expanded in response to pH variation, thereby providing a potential
underlying trigger for smart drug delivery.

4.2 Experimental Section
4.2.1 Materials
Diisopropylamine, azobisisobutyronitrile (AIBN), di-tert-butyl dicarbonate and
N-vinyl-2-caprolactam (VCL) were obtained from Sigma-Aldrich. Tetrahydrofuran
(THF), n-butyllithium and trifluoroacetic acid (TFA) were obtained from Acros.
Deuterated dimethyl sulfoxide (d6-DMSO) and chloroform (CDCl3) were obtained from
Cambridge Isotope Laboratories, Inc. Hexanes and dichloromethane (DCM) were
purchased from Fisher Scientific. All reagents were used as received unless otherwise
noted.
4.2.2 Characterization
1

H-NMR (300 MHz) spectra were recorded on a Varian Mercury 300 NMR

spectrometer. Fourier transform infrared spectroscopy (FT-IR) was carried out using
potassium bromide pellets on a Bio-RAD FTS6000 FT-IR spectrometer. Gel permeation
chromatography (GPC) was performed at room temperature using PL-GPC 50 Plus
(Polymer Laboratories, Inc.) with a refractive index detector. N, N-Dimethylformamide
was used as the carrier solvent at a flow rate of 1.0 mL/min. Standard monodisperse
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polystyrenes (Polymer Laboratories) were used for calibration. Thermogravimetric
analysis (TGA) was performed on Q-50 (TA Instrument) at a heating rate of 20 °C/min in
a nitrogen atmosphere. The degree of ionization of the copolymer at various pH values
was determined from potentiometric titration curves. Polymer solutions (1 mg/mL) were
titrated with 0.1 mol/L NaOH. pKa was estimated from the titration curve. The degree of
ionization was then calculated as α =

b

5cdefcg

, α = [1 / (1 + 10 (pKa-pH))].

4.2.3 Synthesis of carboxylated VCL homopolymer (COOH-PVCL-H)
Monomer of 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam (TBVCL) was
synthesized as described previously.[178] TBVCL (1.195 g, 5 mmol), AIBN (0.008 g,
0.049 mmol) and freshly distilled THF (5 mL) were added into a 50 mL flask, and
subjected to three freeze-thaw cycles to remove oxygen. Polymerization reaction took
place at 65 °C for 24 h. The polymer was then precipitated in hexane, redissolved in THF
and reprecipitated in hexane for purification. The obtained polymer (COOH-PVCL-BOCH, 160 mg, 14% yield) was dried in a vacuum oven at 55 °C overnight (Mn = 5,400
g/mol). The carboxyl groups (-COOH) were recovered by removing the t-BOC protecting
groups using TFA. Briefly, PVCL-COOH-BOC-H was dissolved in DCM followed by
the addition of TFA. After reacting for 3 h, the polymer was recovered by solvent
evaporation and dried in a vacuum oven at 100 °C overnight.
4.2.4 Synthesis of carboxylated VCL copolymer (COOH-PVCL)
In a typical procedure (Figure 40), TBVCL (0.478 g, 2 mmol), VCL (2.5 g, 18
mmol), AIBN (0.049 g, 0.3 mmol) and freshly distilled THF (10 mL) were added into a
35 mL reaction tube.
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Figure 40. Synthesis of the monomer 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam
(TBVCL) and partially or fully carboxylated PVCL polymers. Intramolecular hydrogen
bonding was shown in polymers 3 and 5.
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The mixture was then subjected to three freeze-thaw cycles to remove oxygen.
Polymerization reaction took place at 65 °C for 24 h. The polymer was then precipitated
in hexane for purification. The obtained polymer (COOH-PVCL-BOC) was dried in a
vacuum oven at 55 °C overnight. The yields were above 80%. The carboxyl groups (COOH) were recovered by removing the t-BOC protecting groups using TFA. Briefly,
COOH-PVCL-BOC was dissolved in DCM followed by the addition of TFA. After 3 h of
reaction, the polymer (COOH-PVCL) was recovered by solvent evaporation followed by
precipitation in hexane and dried in a vacuum oven overnight.
4.2.5 Reactivity study
A typical experiment is described below. TBVCL (69.73 mg, 0.29 mmol) and VP
(35.51 mg, 0.32 mmol) were firstly mixed in CDCl3 (0.5 mL), with the initiator AIBN
(1.5 mg, 0.009 mmol). Pyridine (4.94 mg, 0.06 mmol) was added as an external standard.
The mixture in CDCl3 was then placed in the NMR spectrometer for the initial spectrum
collection and frozen in a -20 °C fridge to quench any polymerization at room
temperature. After reaction in the oil bath at 65 °C for 20 minutes, the NMR tube was
taken out and quenched in a -20 °C fridge before measurement. Similarly, two other
NMR tubes with different compositions of TBVCL and VP were prepared and the same
procedures were followed. The experiments for determining reactivity values of VCL and
VP were also carried out using the same procedures described above.
4.2.6 Cloud point measurement
The transmittance for the aqueous polymer solution was measured with a UVvisible spectrophotometer (Biomate 5 from Thermospectronic) at 540 nm by following
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the turbidity of the polymer solution as a function of temperature. Cloud point was
defined using the heating curve as the temperature at which the transmittance was 50% of
the value at room temperature. A heating/cooling rate of 0.2 °C/min was used.
Concentrations of all polymer solutions were 2.5 mg/mL.
4.2.7 In vitro cytotoxicity study
In vitro cytotoxicity of the COOH-PVCL copolymer was examined using the
NIH/3T3 fibroblast cell line. Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (Fetal Clone III, Fisher), 1% Lglutamine and 1% penicillin/streptomycin. Cells were maintained at 37 °C, 5% CO2 and
95% relative humidity. Prior to cytotoxicity test, cells were harvested using trypsin–
ethylenediamine tetraacetic acid (EDTA)–PBS solution (0.25% trypsin–0.038% EDTA)
and diluted to a density of 1 × 105 cells/mL. The cell suspension was added into 96-well
plates at 100 µL/well, and cells were allowed to attach overnight. Cell culture medium
was then aspirated and replaced with fresh medium supplemented with COOH-PVCL at
different concentrations ranging from 0.1 to 10 mg/mL. Cells were incubated overnight
and polymer cytotoxicity was determined using an MTT assay (Promega, CellTiter 96)
according to the manufacturer’s instruction. Negative (without COOH-PVCL) and blank
(without cells) controls were also included. Statistical analysis was conducted using
Student’s t-test.
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4.2.8

LBL

assembly

of

COOH-PVCL/PVCL

monitored

by

Quartz
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microgravimetry (QCM)
QCM measurements were conducted at room temperature using a Q-sense device
(E4) with a flow cell (Q-Sense AB, Västra Frölunda, Sweden). A gold-coated 5 MHz
AT-cut crystal was excited at multiple overtones, and the change in the resonance
frequency was recorded. After deposition of the initial layer of PEI (1.5 mg/mL), the
chamber was washed with water, after which the solution of COOH-PVCL (0.5 mg/mL,
pH = 3.0) was introduced into the chamber and allowed to adsorb for 5 min.
Subsequently, the chamber was washed again with HCl (pH = 3.0) and then filled with
PVCL solution (0.5 mg/mL, pH =3.0), allowing an adsorption time of 5 min. The
multilayer film was then assembled by alternating incubations between COOH-PVCL
and PVCL.

4.3 Results and Discussion
4.3.1 Polymer synthesis and characterization
To integrate additional functionalities such as carboxyl groups while maintaining
the structural continuity of the caprolactam ring, a derivative of VCL monomer (TBVCL)
containing a protected carboxylic acid side group was synthesized via nucleophilic
substitution of VCL at the α–position with tert-butoxycarbonyl group (Figure 40).[179]
This monomer was previously reported specifically for applications as deep UV
photoresists for lithography[179-185], and to our best knowledge there is no prior study
of its potential as smart biomaterials.
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Chemical structures of TBVCL monomer and its homopolymer were confirmed
with 1H-NMR (Figure 41). The characteristic peak of t-BOC at 1.46 ppm was observed in
the monomer structure (Figure 41a).

Homopolymers of carboxylic acid functionalized

PVCL (COOH-PVCL-H) were obtained by polymerization of TBVCL followed by TFA
deprotection. The polymer preparation process was monitored with 1H-NMR by
following the disappearance of characteristic peaks of the double bond in the monomer
(Figure 41b, peaks at chemical shifts 4.41-4.57 and 7.29-7.44 ppm) and the absence of
the t-BOC peaks in COOH-PVCL-H (Figure 41c).
The TBVCL monomer allowed us to introduce a controllable amount of
carboxylic acid groups in the VCL polymer pendent chains to acquire pH-sensitivity,
using simple free radical copolymerization of VCL and TBVCL. As TBVCL bears close
structural resemblance to that of VCL, it is expected that the reactivities of these two
monomers will be similar comparing to that between VCL and methacrylates/acrylates,
thus allowing for easier control of the copolymer compositions. Based on the results of
1

H-NMR (Figure 42a, peaks 1 and 4), a molar feed ratio of 9 : 1 VCL : TBVCL resulted

in a composition of 5.92:1 of the two monomers in the final copolymer (equivalent to
14.4 mol % TBVCL). This compositional drift is significantly lower than that reported in
copolymerization of VCL with MAA, where a 9:1 VCL : MAA molar feed ratio yielded a
1:1 ratio of VCL to MAA in the copolymer (50 mol % MAA).[186] It indicates that: (1)
the disparity of reactivity between VCL and its functional analogue TBVCL is much less
than that between VCL and MAA;

116

d6-DMSO

c

b
8

1

a

2

34

5,6,7
ppm

Figure 41.

1

H-NMR
NMR spectra of (a) monomer TBVCL in CDCl3, (b) protected

homopolymer COOH-PVCL
PVCL-BOC-H in CDCl3, and (c) deprotected homopolymer
COOH-PVCL-H in d6-DMSO.
DMSO.
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Figure 42. 1H-NMR
NMR spectra of (a) protected copolymer COOH
COOH-PVCL-BOC14,
BOC14, (b) acid
deprotected COOH-PVCL14,
PVCL14, (c) protected copolymer COOH
COOH-PVCL-BOC9,
BOC9, and (d) acid
deprotected COOH-PVCL9.
PVCL9. CDCl3 was used for all polymers.
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and (2) TBVCL is more reactive than VCL, as a higher than theoretical percentage (10
mol %) of TBVCL was incorporated into the copolymer. The latter holds significance on
its own, as this could potentially enable further development of functional copolymers
containing thermo-sensitive VCL structures. A detailed study to determine the reactivity
ratios of TBVCL with VCL is described later.
In addition to 1H-NMR, the copolymer composition was further confirmed by
TGA. As shown in Figure 43a, homopolymer of TBVCL (COOH-PVCL-BOC-H) started
to lose weight at 203 °C, characteristic of the spontaneous thermolysis of the t-BOC
groups into carbon dioxide (CO2) and isobutylene (C4H8). At 400 °C, a typical mass loss
from the PVCL structure was observed. The copolymer (COOH-PVCL-BOC14) also
possessed the above two regions of mass loss (Figure 43b), and the percentage of t-BOC
loss was used to calculate molar ratio of TBVCL in the copolymer as 13.6 mol %, which
is comparable with the NMR result.
The chemical structures of the homopolymer and copolymers were also confirmed
by IR spectra (Figure 44). The characteristic band at 1630 cm-1 corresponding to the C=C
stretching of the vinyl group in the monomer TBVCL (Figure 44a) disappeared in all
polymer structures. The strong absorbance peak around 1637 cm-1 in the monomer and all
the polymers are assigned to the C=O stretching of the amide carbonyl group. The peak
originating from the ester C=O stretching in t-BOC around 1735 cm-1 was observed in
polymers containing t-BOC groups (COOH-PVCL-BOC-H (Figure 44b) and COOHPVCL-BOC (Figure 44d)).
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Figure 43. TGA spectra of protected TBVCL homopolymer COOH-PVCL-BOC-H (a),
protected copolymers COOH-PVCL-BOC14 (b) and COOH-PVCL-BOC9 (c).
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Figure 44. IR spectra of (a) monomer TBVCL, (b) protected homopolymer COOHPVCL-BOC-H, (c) deprotected homopolymer COOH-PVCL-H, (d) protected copolymer
COOH-PVCL-BOC14, and (e) deprotected copolymer COOH-PVCL14.

121

Broad peaks from 2200 to 3600 cm-1 were assigned to the -OH stretching in the -COOH
groups of the deprotected homopolymer COOH-PVCL-H (Figure 44c) and copolymer
COOH-PVCL (Figure 44e).
4.3.2 LCST behaviors of COOH-PVCLs
The key rationale of introducing carboxylic acid groups in the VCL polymer
structure is to modulate its thermo-sensitivity with pH. Transmittance at 540 nm of the
carboxylated copolymer solutions at different pH values was studied using a UV-vis
spectrometer for cloud point (Tc) measurements. As summarized in , PVCL
homopolymer and two PVCL copolymers with comparable molecular weights but
different amounts of carboxylic acid groups (COOH-PVCL9 and COOH-PVCL14) were
prepared to specifically study the carboxylic acid groups and compositional effects on the
thermo-sensitive properties. The molecular weights (Mn) for PVCL, COOH-PVCL-9 and
COOH-PVCL14 were 3100, 2600, 2600 g/mol respectively. It is important to maintain
the molecular weights of these polymers consistent as studies have shown that the LCST
of PVCL is also dependent on molecular weight.[187] Generally, as the molecular weight
of PVCL increases, its LCST will decrease.
Figure 45 shows that not only the copolymers retained thermo-sensitivity of
PVCL, but its phase transition temperature can also be varied as a function of solution pH
by modulating the amount of carboxylic acid groups in the copolymer. Specifically, cloud
point of COOH-PVCL9 increased from 35 °C to 44 °C as the pH of solution changed
from 2 to 7.4 (Figure 45a).
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Table 3. Molecular weight and compositional data of PVCL containing polymers

polymer
PVCL
COOH-PVCL9
COOH-PVCL14
a

TBVCL amount (mol %)
in feed
in polymer
a
2.5
8.9
7.4b
10
13.6a
14.4b

Mn
(g/mol)

Mw/Mn

3,100

3.06

2,600
2,600

2.67
2.76

Estimated from TGA. b Estimated from 1H-NMR.
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Figure 45. Phase transition profiles of 2.5 mg/mL of (a) COOH-PVCL9 and (b) COOHPVCL14 in 0.1 M phosphate buffered saline at different pH values. (c) Cloud points (Tc)
of various COOH-PVCLs at different pH values. The dash line represents the Tc of
PVCL homopolymer at pH 7.4. (d) pH vs degree of ionization for COOH-PVCLs at room
temperature.
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When the amount of carboxylated VCL increased to 14.4 mol %, a broader range of
cloud points was observed (Figure 45b), spanning from 29 °C to 64 °C as the solution pH
increased from 2 to 7.4. In addition, the cooling curves (represented by open symbols in
Figure 45a and b) overlapped well with the heating curves, demonstrating good
reversibility of the thermo-responsive PVCL copolymers with little thermo-hysteresis. It
can also be inferred from the thermo-hysteresis results that the positions of the spinodal
curve and binodal curve for the PVCL copolymer will be very close to each other on its
phase diagram, if it were constructed experimentally.
The observed pH-dependent behavior of the PVCL copolymers can be explained
by the hydrophilic/hydrophobic balance between the thermo-dependent hydrophobic
lactam unit and the ionizable –COOH groups. Based on the titration curves (d)
the pKa values of COOH-PVCL9 and COOH-PVCL14 were determined to be 3.1 and
3.2, respectively. Thus, at pH 2 the carboxylic acid groups of the copolymers are partially
deprotonated, and at pH 7.4 fully deprotonated. Compared with homopolymer PVCL, the
carboxylic acid groups could either decrease or increase Tc of the copolymer, depending
on whether carboxylate groups (i.e. protonated form of carboxylic acid, -COOH) or
deprotonated carboxylic acid groups (-COO-) dominated in the polymer structure. On one
hand, carboxylate groups lead to more hydrophobic structures from the likely
intramolecular hydrogen bonding (shown in Figure 40), resulting in a lower Tc. On the
other hand, deprotonated carboxylic acid groups, which increase hydrophilicity of the
polymer, would require a higher Tc to compensate for the enhanced hydrophilicity.[87,
188] As shown in Figure 45c, Tc of COOH-PVCL9 at pH 4 was the same as PVCL
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homopolymer, suggesting that the hydrophilic effect of the ionized -COO- groups
balanced the hydrophobic effect of the protonated –COOH groups at that pH. However,
Tc of COOH-PVCL14 at the same pH was 7 °C lower. Considering that COOH-PVCL14
has a slightly higher pKa than COOH-PVCL9, I expect that at pH 4 less carboxylic acid
groups are ionized/deprotonated for COOH-PVCL14, leading to a higher percentage of
hydrophobic –COOH groups and therefore a lower Tc.
Another observation of the thermo-sensitivity studies is that as pH increased, the
Tc for both copolymers increased as well, since more –COOH groups were ionizing and
the polymer became more hydrophilic. A more dramatic increase was observed for
COOH-PVCL14 due to the higher molar percentage of carboxyl groups. Although only
two copolymer compositions were studied here, I can postulate that a further increase of
the molar percentage of TBVCL in the copolymer will likely lead to a wider range of Tc
as a function of pH. I have observed that for the deprotected homopolymer of TBVCL
(COOH-PVCL-H), its solution at pH 4 remained cloudy even at 4 °C; and at pH 5, the
solution remained clear until the temperature reached 95 °C (data not shown). These
observations can be explained by the very high concentration of –COOH groups, which
both further improve hydrophobicity at low pH and hydrophilicity at high pH.
Additionally, the homopolymer COOH-PVCL-H was not soluble in pure water due to
strong prevalence of intra- and intermolecular hydrogen bonding. I also examined the
phase behavior of homopolymer PVCL at pH 2 and 5, and the corresponding Tc values
were the same as that at pH 7.4, indicating the thermo-responsive behavior of
homopolymer PVCL lacks pH sensitivity.
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It is also worth noting the sensitivity in the phase transition behavior of the copolymers.
As shown in , temperature sensitivity was obtained by measuring the temperature range
corresponding to transmittance change from 90% to 10%. Unlike other reported pHsensitive thermo-responsive polymers,[87, 177] where sharp phase transition is limited to
those with a small amount of acidic component (i.e. less than 3-5 mol %) at certain pH
values (pH 5.0 – 6.5), our system demonstrated that even at a high 14 mol % of
functionalization, these copolymers responded sharply to both pH (from 2.0 to 7.4) and
temperature the same way as the PVCL homopolymer (Figure 46). Such improvement
could be attributed to the well maintained continuity of the thermo-dependent lactam
groups in the polymer structure, allowing sufficient polymer aggregation even in the
presence of high amounts of ionic groups. The importance of sharp phase transition is
evident as it will boost the sensitivity of intended biomedical applications of these smart
biomaterials, such as molecular switching and drug delivery.
4.3.3 Cytotoxicity study of COOH-PVCL
It is well known that PNVP has been widely used in biomedical applications.[68]
Considering the structural similarity between PVCL and PNVP, PVCL based polymers
have also been proposed for biological applications. It was shown that PVCL
homopolymers were well tolerated at various concentrations (0.1-10.0 mg/ml).[189] To
study how the incorporation of carboxyl groups affects biocompatibility of PVCL, I used
fibroblast cells to measure cytotoxicity of COOH-PVCL copolymers. As shown in Figure
47, COOH-PVCL was non-toxic to the cells at concentrations up to 2 mg/mL.
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Figure 46. Influence of chemical compositions on the temperature sensitivity of phase
transition. Top and bottom bars of each data point represent the temperature at 90% and
10% of the solution transmittance, respectively.

128

Figure 47. NIH/3T3 fibroblast cells viability after overnight incubation with different
concentrations of COOH-PVCL copolymers. Cells without polymer treatment served as a
negative control. Data shown are average ± STD (n = 3).
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Upon further increase of the polymer concentration to 10 mg/mL, the cell
viability significantly decreased (p < 0.01) as shown by the reduction in the MTT assay
absorbance, an indication of decrease of mitochondrial activity in cells. It is likely that
higher concentrations of the carboxylated polymer lead to acidification of the culture
medium indicated by the color change of medium, thus affecting cell growth. These
results suggest that the synthesized functional PVCL copolymer is biocompatible
depending on the concentrations applied.
Although this new biocompatible PVCL-derived dual-responsive polymers can
have various biomedical applications where the use of smart biomaterials are desirable, I
am particularly interested in its use for drug delivery from the surface of biomedical
implants. As the LCST of this PVCL copolymer at pH 5.0, a pH condition featured in
inflamed tissues,[34, 88, 190] is drastically different from that at normal
physiologicaltissue of pH 7.4, I could use such characteristics to engineer multilayers on
the surface of biomedical implants and achieve inflammation triggered drug delivery. The
idea is to assemble multilayers with this dual-responsive PVCL copolymer as one of the
components, and upon inflammation induced tissue acidosis, it leads to the molecular
conformational changes due to its associated reduction of LCST, which will subsequently
change the properties of the multilayers and enable drug release. With this biocompatible
dual-responsive polymer, I hope to improve the correlation and control between drug
treatment and the extent of tissue response to biomedical implants in future studies.
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4.3.4 Reactivity study
In order to expand the application of TBVCL, copolymerization with other
biomaterials-related monomers is a good option. The reactivity values of these monomer
pairs are therefore of our interest. There are many mathematical approaches to calculate
reactivity values. Among these methods, Kelen and Tudos (K-T) method is chosen for
my study due to its relative simplicity and popularity. Depending on the molecular
structures, different experimental techniques could be employed including TGA, FTIR,
UV, NMR, etc. The common objective for these experiments is to obtain compositions of
the two monomers before and after composition. In my case, NMR was used due to the
distinctive monomer peaks in the spectra. To test my method, two commercially available
monomers (VCL and VP) were firstly studied.Small amounts of VCL and VP were firstly
mixed in CDCl3 at a predetermined feeding ratio. Pyridine was added as an external
standard. In a quantitative NMR study, internal standard, which means a peak belonging
to one of the reactants, is preferred if possible. However, in this case, there is no such
suitable internal standard peak. Therefore, an external standard is necessary and the
choice is based on the following conditions. Firstly, the standard peak needs to be clearly
distinguished from other peaks. Secondly, the standard chemical cannot react with
monomers. Thirdly, the chemical should be stable at the polymerization temperature, 65
°C. Based on the above limits and the spectral information from VCL and VP, one
possible region of standard peak was identified at the lower chemical shift. Common
solvents were screened and pyridine was finally chosen as the external standard satisfying
the above requirements.
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The mixture in CDCl3 was firstly placed in the NMR spectrometer for the initial
spectrum collection. After reaction in the oil bath at 65 °C for 20 minutes, the NMR tube
was taken out and quenched in a -20 °C fridge before measurement. Similarly, two other
NMR tubes with different compositions were prepared and the same procedures were
followed. The above data (the NMR spectra are shown in Appendix Figure 53-64) were
plotted according to the widely used linear graphic K-T method.[191] The above
procedures are also summarized in Figure 48. And the reactivity values were obtained
from the slope and intercept. The K-T method is based on the following equation:
j

h = iQ + l m −
k

j

k
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where r1, r2 are the reactivity values for monomers. Other parameters are defined
by the following equations:
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Figure 48. Schematic illustration for reactivity valu
value measurements.
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where M1, M2 are the molar amount of the two monomers at the starting point t.
dM1, dM2 are the amount of monomers reacted during polymerization period. α is an
arbitrary positive constant. A feasible choice is:
y = zs{ so

20

where Fm and FM are the lowest and highest values of F, respectively.
There is one constraint on the K-T method. It requires the monomer conversion to
be rather low (< 20%). In this case, I kept the conversion below 15%. Detailed
calculation was carried out and shown in the Appendix (Table 4 and Table 5).
The reactivity values for VP and VCL are calculated to be 4.5 and 0.8
respectively. These data were reported previously in another handbook as 2.8 and 1.7
respectively. My results are consistent with the reference in that the value for VP is larger
than VCL. However, the difference could be attributed to the inherent variance between
different methods for determining reactivity values.
After the experiment for monomer pair of VP and VCL, I proceed to VP and
TBVCL. Using the same method, the reactivity values for VP and TBVCL are
determined as 0.7 and 2.1 respectively.
Attempts have also been made to study VCL and TBVCL. However, this method
did not work because no distinctive peaks in NMR spectra can be identified for
calculation due to the structural similarity between VCL and TBVCL. Even though direct
derivation of the values cannot be obtained, an indirectly approach to compare the
reactivity of VCL and TBVCL is possible and described as followed.
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From the above results, the reactivity values for VP and TBVCL are 0.7 and 2.1
respectively, leading to a conclusion that TBVCL is more reactive than VP. The
reactivity values for VP and VCL are calculated as 4.5 and 0.8 using the same method. It
is concluded that for the order of reactivity, TBVCL > VP and VP > VCL. Therefore, I
inferred that TBVCL is more reactive than VCL. This conclusion also coincides with the
composition of the copolymer of TBVCL and VCL. For example, when VCL and
TBVCL were added at 9:1 molar ratio, the resulting polymer has a molar composition of
6:1. It should be noted that it is still possible to determine the reactivity values of VCL
and TBVCL by other methods such as TGA. Such an approach was not pursued further
due to the limitation of monomer availability.
4.3.5 LBL coating consisting of COOH-PVCL
The synthesized COOH-PVCL is used as the hydrogen bonding donor component
in the LBL process. To simply prove the feasibility of this approach, PVCL was
employed as the hydrogen boding acceptor, which has been demonstrated by other
researchers to be able to form LBL films with another polymeric component. QCM was
utilized to monitor the layer assembly process. As shown in Figure 49, after deposition of
the base layer of PEI, COOH-PVCL could be adsorbed onto the PEI layer. However,
further alternately flowing PVCL and COOH-PVCL could not deposit any appreciable
amounts of polymers onto the Au surface. The underlying reasons could be the low
density of hydrogen bonding donor groups, resulted from low molecular weight of
COOH-PVCL or the small amount of carboxylic acid groups available on the polymer
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chain. The weak hydrogen bonding interaction from the current polymer pair did not
provide sufficient force for stable multilayers formation.
Even though the above exploratory experiment did not result in successful
multilayer deposition, further improvements could be concentrated on increasing the
polymer molecular weight or percentage of COOH groups to realize biocompatible LBL
coatings.
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PEI

COOH-PVCL

PVCL

COOH-PVCL

PVCL

Figure 49. A QCM plot showing the change in frequency (proportional to adsorbed mass)
as a function of the adsorption and build-up of multilayers of COOH-PVCL/PVCL.
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4.4 Conclusions
I have successfully integrated pH and thermo-sensitivity for PVCL polymers by
maintaining the structural continuity of the caprolactam ring while introducing carboxyl
groups via copolymerization with TBVCL, a functional derivative of VCL. The cloud
point of the copolymer can be tuned from 29 °C to 64 °C by changes of solution pH from
2 to 7.4. Cytotoxicity studies of the copolymer on NIH/3T3 fibroblasts showed good
biocompatibility up to a polymer concentration of 2 mg/mL. The high content of the
functional carboxyl groups in the copolymer will also enable further conjugation of
bioactive molecules for broader applications in biotechnology and drug delivery.
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Chapter 5
Summary and Future Work
A mutli-functional approach to combat the tissue response from brain to MEAs
was designed. Anti-inflammatory and anti-oxidant therapeutics were employed to achieve
the objective. Individual polymer therapeutic was developed and the their properties were
fully characterized. The polymers structure and the therapeutic loading capacity are
controllable. The in vitro cell studies showed that they maintained the therapeutic effects.
These polymeric therapeutics were further successfully incorporated onto the silicon
substrate, as the main materials for the neural implants. Also some key design features
were demonstrated such as the pH-responsive release of anti-inflammatory prodrug,
dissociable coatings in the brain environment, and complex coatings structure consisting
stable and unstable components. Furthermore, a smart polymer responsive to pH and
temperature was synthesized and characterized, with the potential to be incorporated in
the complex design to realize advanced therapeutic delivery system.
The specific conclusions in this dissertation were listed below:
1.

A poly(N-vinyl pyrrolidone) based glucocorticoid-polymer prodrug was

synthesized by conjugating prednisolone to functionalized PNVP via a hydrazone
linkage.
2.

pH sensitivity of drug release from the poly(N-vinyl pyrrolidone) based

prodrug was observed under conditions mimicking inflammation-induced tissue acidosis,
as hydrolysis of the hydrazone linkage was enhanced under acidic pH.
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3.

Poly(N-vinyl pyrrolidone) based prodrug and its released products

demonstrated good biocompatibility with neurons. Neural culture showed that both the
prodrug and its precursor polymer were non-toxic to neurons and did not alter the ability
of neurons to maintain neurite extensions, reassuring further application of this prodrug
to mitigate inflammation at the neural interface.
4.

Bioactivity of the poly(N-vinyl pyrrolidone) based prodrug and its

released free drug were studied with RAW264.7 macrophages in vitro, where inhibition
of nitric oxide production was observed, suggesting the desired anti-inflammatory effect.
5.
hydrogen

Poly(N-vinyl pyrrolidone) based prodrug was also compatible with the
bond-driven

LBL

assembly

technique.

Multilayers

of

poly(acrylic

acid)/prodrug were successfully deposited onto silicon substrates and quartz plates. The
layers were destructible when incubated in physiological pH, which could be beneficial
for neural electrodes.
6.

Poly(N-vinyl pyrrolidone) based prodrug can serve as a promising and

versatile drug delivery system. It can be easily applied to neural electrodes without
compromising the electrical property of the implant, and can potentially realize tissue
response-regulated drug release based on tissue acidosis. This system allows localized
pharmacological interventions that deliver anti-inflammatory drugs based on the extent of
inflammation without interfering with the electrical properties of the neural electrodes.
7.

Compositionally controllable antioxidant polymeric therapeutics PVTs

were prepared by copolymerizing monomers of triethylene glycol methyl acrylate
(TEGMA) and α-tocopheryl acrylate (VeAc). In contrast to the poor water solubility of
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Ve, solubility of the PVT prodrug in water can reach as high as 3.1 mg/mL (equivalent to
500 µM Ve) by tuning the copolymer composition.
8.

The PVT prodrug was non-cytotoxic toward A172 human astrocytes.

Furthermore, PVT was able to protect astrocytes against oxidative stress exerted by
hydrogen peroxide in vitro. Using a free radical scavenging assay, the protection
mechanism was suggested to be attributed to the hydrolysis of the labile ester linkage and
release of the active Ve.
9.

Multilayers containing PVT with tunable stability at physiological

condition could be achieved simply by engineering the layer composition. PVT was
successfully deposited on silicon (Si) substrates with poly(acrylic acid) (PAA) or tannic
acid (TA) using the LBL technique mediated by hydrogen bonding. Ellipsometry and
quartz crystal microbalance (QCM) data showed that the multilayers of PAA/PVT were
destructible at physiological pH. In contrast, multilayers of TA/PVT were stable.
10.

Functionalized

temperature-

and

pH-sensitive

poly(N-vinyl-2-

caprolactam) polymers were prepared by copolymerizing monomers of VCL and a VCL
derivative, TBVCL..
11.

Sharp, complete and reversible phase transitions of the copolymers with

little hysteresis were shown to be pH-dependent, with cloud points ranging from 35 °C to
44 °C for COOH-PVCL9, and 29 °C to 64 °C for COOH-PVCL14, upon pH change from
2.0 to 7.4.
12.

Biocompatibility cytotoxicity assay demonstrates that the functionalized

PVCL copolymers were biocompatible with NIH/3T3 up to 2 mg/mL.
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13.

The functionalized PVCL copolymers hold potential to be used for drug

delivery from the surface of biomedical implants. The idea is to assemble multilayers
with this dual-responsive PVCL copolymer as one of the components, and upon
inflammation induced tissue acidosis, it leads to the molecular conformational changes
due to its associated reduction of LCST, which will subsequently change the properties of
the multilayers and enable drug release.
Based on above conclusions in this dissertation, future work is proposed,
including:
1.

In vitro study of anti-inflammatory and anti-oxidant prodrugs on primary

cells such as brain derived microglia, astrocytes, and neurons.
2.

Validation of the efficacy of different films in improving the

biocompatibility of the neural implant in a rat model. These films will include LBL
coatings with either anti-inflammatory or anti-oxidant prodrug. Furthermore, possible
synergistic effect will be examined when the film contains both prodrugs.
3.

Modulation of the molecular weight and composition of functional

poly(N-vinyl-2-caprolactam), and incorporation of these polymers in multilayered films
as a smart drug delivery platform responsive to temperature and pH, toward neural
implant applications.
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APPENDIX

Figure 50. Fluorescent images and intensity in the diffused region of the fluorescent prodrug
analog.
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Table 4. Calculation for the reactivity of VCL and VP.
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Table 5. Calculation for the reactivity of TBVCL and VP.
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Figure 51. K-T plot for the reactivity study of VCL and VP.
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T plot for the reactivity study of TBVCL and VP.
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1

Figure 53. NMR spectra of VCL and VP at a molar feeding ratio of 0.5, before
polymerization.
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Figure 54. NMR spectra of VCL and VP at molar feeding ratio of 0.5, after
polymerization at 65 °C for 20 minutes.
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Figure 55. NMR spectra of VCL and VP at molar feeding ratio of 1, before
polymerization
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Figure 56. NMR spectra of VCL and VP at molar feeding ratio of 1, after polymerization
at 65 °C for 20 minutes.
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Figure 57. NMR spectra of VCL and VP at molar feeding ratio of 2, before
polymerization
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Figure 58. NMR spectra of VCL and VP at molar feeding ratio of 2, after polymerization
at 65 °C for 20 minutes.
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Figure 59. NMR spectra of TBVCL and VP at molar feeding ratio of 0.5, before
polymerization.
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Figure 60. NMR spectra of TBVCL and VP at molar feeding ratio of 0.5, after
polymerization at 65 °C for 20 minutes.
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Figure 61. NMR spectra of TBVCL and VP at molar feeding ratio of 1, before
polymerization.
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Figure 62. NMR spectra of TBVCL and VP at molar feeding ratio of 1, after
polymerization at 65 °C for 20 minutes.
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Figure 63. NMR spectra of TBVCL and VP at molar feeding ratio of 2, before
polymerization
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Figure 64. NMR spectra of TBVCL and VP at molar feeding ratio of 2, after
polymerization at 65 °C for 20 minutes.
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